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Abstract:  Nearly 10 million deaths are caused by cancer around the globe every year.  
Blood cancer is responsible for roughly 86,000 deaths in the United States.  Patients’ 
lifespan is improving as new technologies and controlled drug delivery techniques emerge.  
Cancer drug resistance and high required drug dosage remain the major hurdles towards 
improving cancer treatment.  Nutraceuticals, such as resveratrol, are proven to be safe, and 
chemo-preventive action on a wide array of cancer have been used as a method to improve 
the sensitivity of the other drugs in combination therapy.  Nutraceuticals, however, are non-
specific, sparingly soluble in aqueous solution, and bioavailability in vivo is very low, lead-
ing to limited therapeutic effectiveness even at higher doses.  Clinical trials with 150 
mg/day of resveratrol given to healthy volunteers for 30 days showed plasma levels in the 
nanomolar range.  Hence, arises the need for drug delivery of combination therapy to re-
duce the dose required and drug resistance.  In this project, resveratrol is combined with 
leukemia-targeted small interfering RNA (siRNA), and encapsulated in electrospun micro-
fibers, and holo-transferrin PEG-liposomes, respectively.  Experiments were performed 
using single K562 cell cultures, as well as K562 and HUVECs co-cultures.  Resveratrol 
(40 µM) content was analyzed using HPLC and cell viability was assessed using Annexin 
V (Non-viable), and Propidium Iodide (PI) (Necrotic) based flow cytometry.  Electrospun 
microfibers with resveratrol were made using 1:1 PCL-GT blends.  BCR-ABL siRNA (36 
nM)-encapsulated holo-transferrin-conjugated PEG-liposomes were characterized using 
dynamic light scattering, and transmission electron microscopy.  RT-qPCR was performed 
to assess silencing BCR-ABL gene.  The combination therapy was additive, and controlled 
release in a timely manner resulted in 94.32 (±1.70)% K562 cells non-viability after 8-days 
of incubation.  A computational fluid dynamics (CFD) model was developed in this project 
to assess the fluid flow impact on resveratrol release from electrospun microfibers.  A cus-
tom-built bioreactor was designed to validate the model and study the stability of resvera-
trol in cell medium.  Concentration profiles over 5 days were generated.  The model sug-
gested that perfusion velocity may not have a significant effect relative to cellular uptake 
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Cancer treatment has gained tremendous attention due to its global impact.  Statistically, 18.1 mil-
lion new cases of cancer will be diagnosed globally in 2018, of which, 9.6 million patients are 
expected to die [1].  Chronic Myeloid Leukemia (CML), also referred to as chronic myelogenous 
leukemia, is a type of blood cancer. It starts in the blood-forming cells of the bone marrow and 
invades the blood.  Approximately every 3 minutes, a person is diagnosed with blood cancer in the 
US, and almost 171,550 people in 2016 are diagnosed with leukemia, lymphoma, and myeloma. 
Blood cancer accounts for almost 10.2% of new cancer cases in the US (Figure 1) [2].   
 
Figure 1.1: Estimated new cases of blood cancer in 2016. 
 
Some of the available treatment options, apart from chemotherapy are molecular inhibitors of BCR-
ABL pathway and tyrosine kinase pathway.  Due to significant side effects with such medications, 
alternative therapies have been explored [3].  Supplementation with many nutraceuticals has been 
explored due to their proven safety [4].  
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Resveratrol, a naturally derived product found in red wine, grapes, fruits, peanuts, and pines, has 
been extensively investigated and shown to have a chemopreventive action on a wide array of can-
cer [5].  Resveratrol is, however, sparingly soluble in aqueous solution, and its bioavailability in 
vivo is very low when administered orally, leading to limited therapeutic effectiveness even at high 
doses.  Alternatively, small interfering RNAs (siRNAs), which are 20-25 base pairs in length, have 
been shown to be very effective with local administration in silencing targeted genes since the first 
demonstration in 2010 [6].  However, systemic administration exacerbates side effects.  Further, 
siRNA half-life is near 24 h [7], necessitating a higher dosage.  In order to improve safety, targeting 
is required while minimizing the dosage, so that side effects could be eliminated.  One unique 
approach shown to be more effective in targeting siRNA based delivery to cancer cells is transfer-
rin-receptor based liposomal delivery [8, 9].  I propose combing these two approaches to treat can-
cer for its effectiveness. This is attributed to targeting different cellular pathways, through different 
mechanisms each drug induces.  Hence, combination therapy lowers the probability of drug re-
sistance in cancer cells.  In order to control the release rates independently, two different delivery 
vehicles are explored.  I hypothesize that the synchronized combination treatment through con-
trolled release of each drug, can reduce side effects, and induce higher levels of cancerous cells’ 
non-viability.  To test my hypothesis, the following three aims are investigated: 
Aim 1: Evaluate the influence of controlled release of resveratrol, in combination with siRNA 
on cell viability. Resveratrol-based therapy is hindered by achievable local therapeutic concentra-
tions.  Hence, I will test the controlled release of resveratrol using coaxial electrospun fibers.  
Poly(ε-caprolactone) (PCL) and gelatin (GT) blends were used to load resveratrol, HPLC was used 
to assess the controlled release profile.  I also tested the combination therapy using siRNA, targeted 
towards BCR-ABL pathway to reduce the needed dosage of resveratrol.  A factorial design is per-
formed to evaluate the dosage requirements.  I evaluated the apoptotic and necrotic effects of this 
treatment on K562 cells using Annexin V and Propidium Iodide staining.  In the case of lipophilic 
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resveratrol, fiber configuration showed no significant effect on the release profile.  Upon the con-
trolled release of 40 µM resveratrol from single fibers, roughly 45% non-viable leukemia cells, 
after 8 days of incubation was measured.  However, this percentage dropped to roughly 20% in the 
presence of 36 nM free BCR-ABL siRNA, which lead to further analysis in aim 2.  Detailed find-
ings of aim 1 are described in Chapter III.   
Aim 2: Assess the effect of siRNA-loaded liposomes, in combination with controlled release 
of resveratrol on cell viability.  In order to control the diffusion-dependent release of each drug 
independently, and eliminate any side interaction or side effects, a second delivery system was 
introduced.  K562 cell line was treated with BCR-ABL siRNA-loaded PEG-liposomes.  Liposomes 
123 (±6.65) nm in size were formed using established techniques.  Extrusion and dialysis were 
performed to obtain the desired size and purity.  The surface of liposomes was modified with holo-
transferrin, with 85.9 (±7.30)% conjugation efficiency, and the cell viability analysis was per-
formed.  Roughly 50% of non-viable leukemia cells was measured.  PCL-GT microfibers contain-
ing resveratrol were then used along with siRNA-containing holo-transferrin-derived nano-lipo-
somes.  The treatment was tested in both single cultures of K562 cells, and co-cultures, in the 
presence of HUVECs.  The treatment introduction was tested in a timely manner, showing that the 
delayed addition of liposomes increases K562 non-viability to 92.7 (±2.00)% and 94.32 (±1.70)%, 
in the absence and presence of HUVECs, respectively.  HUVECs non-viability level was signifi-
cantly lower.  Experimental analysis and results are discussed thoroughly in Chapter IV. 
Aim 3: Design a bioreactor to mimic the bone marrow microenvironment, and study the lat-
ter’s effect on the proposed treatment.  Due to the complexity of the biological microenviron-
ment, it is very challenging to experimentally study certain effects of that microenvironment on the 
delivery system.  A cost- and time- effective model was developed to predict these effects.  Since 
liposomes are proposed to be injected intravenously, the main challenge would be predicting the 
release profile of locally-administered micro-fibers in the bone marrow.  In order to understand the 
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various physical effects in the bone marrow microenvironment on the release of resveratrol from 
single fibers, a mathematical model is developed using COMSOL Multiphysics.  This design in-
cluded a cylindrical bioreactor, where inner walls were modified with fiber release of resveratrol.  
The model was used to test several variables, such as blood perfusion rate, cellular uptake, and the 
length of the reactor, on the release profile.  Results showed that the release kinetics are diffusion-
dominated.  Cellular uptake was found to be the main variable affecting the release profile.  The 
model parameters were obtained from literature, and in-house performed experiments, for which 
the stability of resveratrol under various conditions was established, aligning with that in literature.  
The model was successfully validated by performing a flow system experiment, under matching 
conditions such as temperature and flow rate, and analyzing the release of resveratrol using HPLC.  
To further develop the model to mimic the actual bone marrow microenvironment, an outer porous 
layer was added, showing similar simulation results.  These results are presented in Chapter V.   
Broader Impact: The proposed treatment can be applied to different types of cancer.  The pro-
posed two molecules interact additively to inhibit certain cellular pathways leading to apoptosis.  
The delivery systems allow the controlled release of each drug and can be introduced locally.  The 
mathematical model is a powerful tool to predict certain effects of the extracellular environment.  









2.1 Single and multi-drug treatment for leukemia 
Various drugs are investigated for the treatment of leukemia, these drugs are tested individually 
and in combination as shown in Table 2.1.  BCR-ABL is a fusion gene found in most patients with 
CML.  BCR-ABL protein downregulation by siRNA showed a reduction in the corresponding 
mRNA and early and late-stage apoptosis.  It has been shown that 84% protein suppression can be 
achieved (no concentration specified for that suppression level, however, 50 nM and 100 nM are 
recommended) [10]. 
Myricetin, a small molecule inhibitor has shown high inhibition activity of the enzyme (hIMPDH1) 
[11]. That enzyme is partially localized in the nucleus of CML derived cells, or K562 cells (Figure 
2.1). It promotes cell growth by controlling the guanine nucleotide pool size [12].  It has been 
shown that Myricetin Inhibition % of that enzyme reaches 64.78%, with IC50 of 6.98 ± 0.22 µM. 
In comparison, other small molecule inhibitors only caused less than 25% inhibition with IC50 of 





Figure 2.1: Microscopic image of K562 cell culture (72 hours of incubation). 
 
Imatinib is a tyrosine-kinase (BCR-ABL) inhibitor that is used in CML (chronic myeloid leukemia) 
chemotherapy (3 µM lowers cell metabolism to around 20%) [13]. Imatinib is FDA approved and 
has passed clinical trials, it is used for CML treatment. Reported side effects include: mild to mod-
erate nausea, myalgias, edema, fatigue, dyspepsia, diarrhea, and skin reaction. These side effects 
occur in less than 10% of CML patients. [14]. More occurring side effects include ocular, such as 
abnormal vision and intraocular pressure (Imatinib dosage is 400 mg/day – 800 mg/day) [14]. The 
side effect is also more occurring as skin reactions, including superficial edema (48-65% of cases 
treated), and macular-papular eruption (~67% of cases treated) [15]. ABL drug-related mutation 
has also been reported [13]. 
PPP2R5C pathway downregulation was studied using PPP2R5C-siRNA which drops the expres-
sion levels of PPP2R5C mRNA and protein to less than 15% [16]. 
Mithramycin is shown to inhibit the regulatory associated protein of mTOR - raptor (which regu-
lates other downstream targets including kinases). Relative expression % of raptor dropped to 25% 
(cells were treated with 30 nM) [17]. However, mithramycin inhibition effect on K562 cells has 
been studied over the past two decades [18]. On the clinical level, it has only been shown effective 
on solid tumors [19]. Hence, it’s expected to be a feasible option for this study.  
As K562 cells are known to be TRAIL-resistant, it’s been shown that this resistance can be sup-
pressed using siRNA or Amurensin G to inhibit cell growth and cause apoptosis. The cytotoxicity 
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effect of TRAIL is induced through SIRT1 downregulation which leads to cell death. It’s been 
shown that cell apoptosis reached roughly 22% when treated with SIRT1 siRNA, and 25 ng/ml of 
TRAIL, while that percentage is roughly 27% when treated with Amurensin G and 25 ng/ml of 
TRAIL [20].   
Rilmenidine proliferation suppression effect has also been studied. Rilmenidine is a selective im-
idazoline I1 receptor agonist, that downregulates BCR-ABL pathway upon binding. It’s been 
shown that the percentage of the apoptotic cells increased from 20%, using rilmenidine alone, to 
42% when used synergistically with doxorubicin [21]. 
VEGF (Vascular Endothelial Growth Factor) has been frequently targeted to inhibit the growth of 
solid tumors. One study shows that VEGF is also expressed in leukemia cells. It’s been shown that 
antisense-VEGF can be used to downregulate the expression of endogenous VEGF which lead to 
roughly 10% cell apoptosis [22].  
Polyphyllin D, a compound derived from Paris polyphylla rhizome (Chinese herb), showed inhib-
itory activity on K562. It was shown that the IC50 is 0.8 M for an inhibition percentage of around 
90%. Induction of apoptosis takes place via the mitochondrial apoptotic pathway, through down-
regulation of BCR-ABL expression levels. Apoptosis of K562 was shown to be 25% using 0.8 µM. 
The suppression levels of BCR-ABL is 40%, while that of Bcl-2 is 85% [23]. 
Gallic acid has also been used to inhibit K562 growth. Gallic acid inhibits cell line growth by 
downregulation of COX-2, inhibition of BCR/ABL kinase, and NF-KB inactivation. Growth inhi-
bition of K562 is gallic acid concentration dependent, where 10 µM causes around 15%, while 75 
µM causes around 80% inhibition [24].  
Some inhibitors resulted in high levels of mRNA/protein suppression, with noticeably low apopto-
sis levels. It is also noticed, apart from resveratrol, that only synergistic effect of Rilmenidine and 
doxorubicin resulted in 42% cell apoptosis, while all other inhibitors resulted in less 30%. These 
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results suggest that despite inhibiting certain pathways with high percentage, cells can still survive 
by undergoing alternative pathways, hence low apoptosis level is obtained. This suggests using a 
dual effect of siRNA with another inhibitor to achieve higher apoptosis level.  
Resveratrol showed both high inhibition and apoptosis rates [25]. It inhibits the Sphingosine kinase 
1 enzyme (SPHK1). This enzyme catalyzes the formation of Sphingosine-1-phosphate (S1P), 
which is mainly involved in regulating proliferation and survival. This study shows that the inhibi-
tion rate of K562 by resveratrol (using MTT assay and ELISA kit) reaches around 63% with a 
concentration of 40 µM. Apoptosis rate with the same concentration reaches 58.28% [25].  
Many drugs have been investigated for their potential in treating cancer.  It is inferred that a com-
bination of multiple drugs gives higher cancer cell death levels.  Although combination therapies 
tackle different cellular pathways in cancer or amplify the outcome of a single target, off-site tar-
geting, and high dosing, are associated with problems.  To address those, delivery devices are de-
signed.  
Table 2.1: Single and combination drugs investigated in leukemia treatment. 
Inhibitor Target Protein/mRNA 
suppression 










Imatinib BCR-ABL 80% cell metabo-
lism suppression 
- 493.603 [13] 















- 170.12 [24] 
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Myricetin  hIMPDH1 64.78% inhibition  - 318.2351 [11] 
siRNA  PPP2R5C 85% suppression of 
mRNA expression  
 13,300 [16] 







75% suppression of 
protein expression 
- 1085.15 [18] 
SIRT1 siRNA 
+ TRAIL 






Amurensin G + 
TRAIL 







VEGF - ≈10% cell 
apoptosis 
38,200 [22] 




2.2 Delivery devices 
Drug delivery refers to methods and techniques, developed for the purpose of transferring a certain 
drug, or multiple drugs, to the site of interest.  Further advantages include lowering the required 
dose to exert an effect on the target and control the release of the drug over a desired period of time.  
In this review, three main methods of delivery are tackled.  Scaffolds, nanoparticles, and electro-
spun fibers.  For purposes of selection, the targeted medium properties, such as porosity, are essen-
tial to consider. 
2.2.1 Scaffolds for cancer drug delivery  
In the field of tissue engineering, highly porous biodegradable scaffolds are utilized to regenerate 
or repair damaged tissues.  Mature cells and stem cells are seeded and allowed to attach to the 
porous structures.  In order to stimulate those cells, stimulants have been sequestered either directly 
in the scaffold or after encapsulation in nanoparticles in order to influence cellular behavior and 
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create a heterogeneous environment.  Similar notion has been extended for delivering molecules 
for cancer therapy.  For example, the microenvironment and cell functionality can be manipulated 
through local gene delivery from scaffolds [26].  Gene delivery using scaffolds have shown im-
proved control upon expression in promoting the regenerated tissue.  Drug release from the scaffold 
is typically controlled by diffusion and cell migration, which limits control upon drug release.  One 
group has shown that scaffolds with magnetic properties can provide remote control to deliver 
molecules such as mitoxantrone, plasmid DNA, and chemokines [27].  
Biomaterials can also be directed for immunotherapy in treating cancer.  A recent review illustrates 
immune therapies using chimeric antigen receptor (CAR)-T cell therapy, among other immuno-
therapies, using various biomaterial carriers  [28].  This review is not re-iterating the mentioned 
reference, however, scaffolds can be combined with the reviewed immunotherapies, to provide 
local immunomodulation.  This avoids systemic toxicity and allows lower dosage administration.  
A recent study has shown that locally delivered cancer drugs from engineered three-dimensional 
scaffolds, can potentially promote systemic antitumor immunity [29].  These recent studies foresee 
that immunotherapy has the potential of transforming cancer treatment in the near future.  Cancer 
immunotherapy future lies mainly in combining T cells, and checkpoint inhibitors for tumor sup-
pression [30]. 
2.2.2 Nanoparticles and ligands in cancer treatment 
2.2.2.1 Nanoparticles in cancer treatment 
Several types of nanoparticles have been investigated for delivery, mainly liposomes and polymeric 
nanoparticles (Figure 3).  A previous study covered the use of polymers in the delivery of siRNA 
[31].  Small molecule cancer therapeutics problems are associated with pharmacokinetics as well 
as the delivery method.  Using polymers can involve the incorporation of nanoparticles, such as 
carbon nanotubes, and gold nanoparticles, to enhance drug delivery.  Although using polymers is 
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advantageous due to properties including, safety, and efficacy, surgery is required to remove the 
non-biodegradable polymer after the drug is released [32].  Delivery of siRNA is the main challenge 
for this type of cancer therapy. Hence, suggesting an effective delivery system is essential for treat-
ment with the latter method. Nanoparticles are favored due to optimal achievable clearance [33].  
Lipid-based nanoparticles delivery of siRNA is preferable to other methods. This potential is 
mainly based on biocompatibility and low toxicity.  
 
Figure 2.2: Schematic representation of liposomes and polymeric nanoparticles. 
 
Endogenous characteristics of siRNA such as negative charge, rigid structure, size, and stability, 
make passive diffusion through cell membrane quite challenging. To address this challenge, endo-
cytosis becomes an effective mechanism of delivery that can be achieved using lipid-based nano-
particles. [34].  Lipid-based nanoparticles are mainly delivered by a sub-category of endocytosis 
called Clathrin Endocytosis.  In this method, vascular internalization of particles occurs with the 
aid of certain proteins, or Catherine, that can induce the formation of vesicles without direct action 
from the cell membrane [35].   
Nanoparticle-based delivery provides various advantages such as increased efficacy, high stability, 
the ability to encapsulate both hydrophilic and hydrophobic molecules, and administer-ability by 
multiple methods [36].  Nanoparticles, however, have a relatively limited carrying capacity, com-
pared to electrospun microfibers.  Premature rupture of the nanoparticle membrane can lead to 
unintended off-target release drug release.  The former self-assembles, and has a bilayer membrane 
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structure, while the latter is composed of biodegradable and biocompatible nanostructures.  Both 
types deliver hydrophilic or hydrophobic molecules, while liposomes can deliver both simultane-
ously by encapsulating each drug in a separate layer.  The inner layer of liposomes encapsulates 
hydrophilic molecules, while the outer layer encapsulates lipophilic molecules.  Drugs are dis-
solved, entrapped or conjugated to the surface of the polymeric nanoparticles [37].  Higher loading 
efficiencies are typically achieved with liposomes (~95%) [38], [39] compared to polymeric nano-
particles (~90%) [40], [41]. 
2.2.2.2 Surface functionalization of nanoparticles 
Ligand-targeted liposomes have shown great potential in many novel delivery systems, with high 
in vivo response due to their active targeting, increased stealth, and controlled drug release (Table 
2.2).  PEG coating (to overcome rapid clearance from circulation) and ligand attachment (to avoid 
non-specific binding) are specifically important to overcome the challenges associated with lipo-
somal delivery systems [42].  
Certain types of ligands (used for a certain type of cancer) provide higher binding efficiency and 
several folds decrease in IC50 value compared to non-targeted liposomes. Peptides, Lactose, mon-
oclonal antibodies, folate, glucose, and transferrin are among the several ligands provided in the 
literature. [42].  For example, cancer cell proliferation requires a high intake of iron, hence cancer 
cells express a high concentration of transferrin receptor [44].  Transferrin and Holo-transferrin 
ligands have been used in the treatment of human leukemia (K562 cells). The former enhanced 
intracellular uptake with fivefold decrease in IC50 (treated with doxorubicin in vitro), while the 
latter has been used with BCR-ABL siRNA delivery (in vitro), and 2.5-folds enhancement in tumor 
uptake (compared to free Bcl-2-siRNA in vivo). Holo-transferrin attachment also showed improved 
tumor growth inhibition, and higher survival time compared to the non-targeted liposomal system. 
[42].  Besides several folds over-expression of the transferrin receptor in malignant cells, transferrin 
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is also expressed in the brain capillary endothelial cells [43].  Accordingly, using transferrin as a 
targeting tool helps to cross the blood-brain barrier, which is an obstacle in many cases. 
Monoclonal antibodies have gained attention in cancer treatment due to overexpression of certain 
differentiation antigens and growth factors on tumor cells, e.g. epidermal growth factor.  Antibodies 
have several affecting mechanisms on target cells, such as agonist activity upon binding to the 
surface receptor, induction of immune pathways, or stromal ablation [44].  Folate receptor is over-
expressed in many tumor cells, such as ovarian, breast, and lung cancer, among others.  This ex-
pression is significantly lower in normal cells.  Folate activates certain cellular pathways, upon 
binding to the folate receptor, which eventually acts upon the nucleus, directly affecting transcrip-
tion  [45].  Nucleolin is another recent targeting method for liposomes and other nanoparticles, to 
deliver drugs such as siRNA and doxorubicin.  Nucleolin is a ribonucleoprotein, which is overex-
pressed in cancer cells and is associated with cell proliferation and apoptosis [46].  It has been 
shown successful inhibition of tumor growth, with no observed non-specific binding  [47].   
Table 2.2:  Ligands in cancer treatment targeting. 
Ligand  Treatment Target  Results Refer-
ences 







K562 Selective in vitro delivery [42] 
Holo-trans-
ferrin 
Bcl-2 siRNA K562 2.5-fold enhancement in tumor 
uptake in vivo 
80% Bcl-2 siRNA downregu-
lation in vitro 
Tenfold decrease in IC50 in 
vitro 
[42] 
mAB Bcl-2 siRNA B-cell lym-
phoma 
Induced apoptosis by im-




Folate Doxorubicin Human cervi-
cal and ovarian 
lymphoma 
Tumor growth inhibition  [45] 
Nucleolin siRNA  MDA-MB-231 
breast cancer 
cells  
Inhibit tumor growth  [46], [47] 
 
2.2.3 Electrospun fibers for small molecules delivery  
Electrospinning is a versatile polymer processing technique for the production of micro and nano 
diameter fibers through an electrically charged jet of the polymer solution.  Characteristic diameters 
of the formulated electrospun fiber vary according to electrospinning conditions, such as voltage, 
and pumping speed.  Nano- and microfibers varying from 630 nm to 6 µm in diameter have been 
formed by varying various solution parameters and processing parameters.  Recent advances in 
electrospinning have facilitated the formation of fibers with desirable structural features such as re-
enforced core, hollow, porous, multicoated and tri-axial fibers will provide unique features for fab-
ricated fibers. Controlling the fiber size and formation techniques have been extensively reviewed.  
Readers could refer to those review articles.  This wide range of structure-dependent features makes 
electrospun fibers a good candidate for many applications (Table 2.3).  Electrospun fibers have 
provided unprecedented opportunities that were recently applied in the field of cancer diagnosis 
and therapy.   
Electrospun nanofibers and microfibers are employed in the treatment, diagnosis, delivery, and 
modeling of cancer.  These fibers possess numerous properties including; high loading capacity, 
extremely large surface area, porosity, and high encapsulation efficiency [48].  Once administered 
in the body, electrospun fibers’ degradation, like other properties, depends on their composition.  
Further information about that and the immune response is found in previous studies [49, 50].  
Electrospun nanofibers and microfibers can be modified in terms of morphology and structure to 
15 
 
serve different purposes.  Different properties were applied in different applications, those include; 
single fiber, multiaxial fibers, and surface functionalized fibers.  Detecting circulating tumor cells 
is a challenge due to their low count in the bloodstream.  Electrospun fibers have recently been 
studied as a potential selective cell capturing method, due to their cell adhesion, and high surface 
area properties. Electrospun polystyrene fibers attached to antibodies were used to detect cancer 
markers such as; alpha-fetoprotein (AFP), and vascular endothelial growth factor (VEGF) [51].  
Ligand conjugated fibers have also been investigated for cancer targeting.  For instance, folic acid 
modified electrospun poly(vinyl alcohol)/polyethyleneimine (PVA/PEI) nanofibers were used to 
specifically detect cancer cells overexpressing folic acid (FA) receptors such as ovarian and pan-
creatic cancer [52]. 
Another application based on the physicochemical properties of the electrospun fibers and their 
ability to selectively adhere to cancer cells.  This property was specifically incorporated in the 
localized photothermal ablation to tumors.  Poly(caprolactone)-based electrospun microfiber scaf-
fold with covalent surface functionalization of graphene oxide (GO) (PCLMF-GO) have enhanced 
selective cancer cell adhesion and proliferation properties. Graphene oxide can be used to enable 
localized photothermal eradication due to its near-infrared absorbance ability [53]. 
Artemisinin, a chemical compound that reacts with iron to produce free radicals, was incorporated 
in cancer cells treated for free radicals’ ability to kill cells.  Electrospun core/shell nanofibers were 
designed for the purposes of targeted delivery and preserve drug bioavailability. Hyperbranched 
poly(butylene adipate) (HB), which is used as a crystal suppressant for artemisinin, is the core 
material, and Poly(vinylpyrrolidone) (PVP) is the shell material.  This delivery system effectively 
reduced prostatic cancer cell viability [54].  Mycophenolic acid (MPA) has been approved to inhibit 
many types of cancer cells growth.  MPA degrades quickly due to liver uptake, hence a delivery 
method is essential to address this issue.  Coaxial fibers of poly(ε-caprolactone) (PCL) core loaded 
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with MPA and PCL shell was used for controlled release of MPA [55].  This fiber system was 
applied to glioblastoma multiforme (GBM) tumor cells, which indicated strong cell suppression.   
In addition to diagnosis, treatment and drug delivery, electrospun fibrous scaffolds (aligned PCL 
fibers) were employed to mimic the extracellular environment of tumors.  A fibrous scaffold with 
random and aligned orientations was designed to study the three-dimensional structure of the ex-
tracellular matrix of breast cancer [56].  Breast cancer cells showed overexpression of transforming 
growth factor β-1 (TGF β-1), which is attributed to their response to the polymer scaffold.  Despite 
promoting cell growth, it has, nevertheless, been shown that TGF β-1 can trigger cellular responses 
such as differentiation and apoptosis [57]. 
Table 2.3:  Electrospun fibers in cancer treatment. 
Electrospun Fiber Application Year Reference 
Polystyrene nanofibers Cancer markers detection (AFP, CEA, 
and VEGF) 
2013 [51] 
PVA/PEI nanofibers FA overexpressing- cancer cells 2016 [52] 
PCL-GO microfibers Breast cancer adhesion/localized pho-
tothermal ablation 
2017 [53] 
HB/PVP core/shell nanofibers Artemisinin delivery to a prostatic can-
cer cell 
2017 [54] 
PCL/MPA / PCL core/shell fibers MPA delivery to (GBM) tumor cells 2017 [55] 




Electrospun microfibers (Figure 2.3) has the potential to deliver higher doses of nutraceuticals due 
to their high surface area, and high carrying capacity.  Microfibers, however, are associated with 
the limitation of systemic administration.  Since the latter is not possible with this method of deliv-
ery, local administration is suggested.  Similar to a bone marrow biopsy procedure, or stem cell 
local administration [58], microfibers can be placed in the bone marrow, for example, to controlla-
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bly release and deliver nutraceuticals with therapeutic effects.  This procedure requires further in-
vestigation, and future research can reveal possible methods for local administration, required 
amounts microfiber, and dosages of delivered therapeutic.  Investigating this approach might be 
challenging and would require in vivo testing, however, local delivery of therapeutic nutraceuticals 
can sensitize the target cells for further targeted treatment.  The latter can be administrated system-







Figure 2.3: Scanning Electron Microscope (SEM) images of electrospun microfibers at dif-
ferent magnifications (a ×9000, b ×3500, and c ×1000). 
 
2.3 Combined drug delivery  
This section will discuss the advantages and challenges associated with delivery systems for com-
bination therapy.  When selecting a delivery method, a researcher is advised to go through the 
following steps: 
1) Define the target tissue/organ/cells, and have a good understanding of the target microenviron-
ment. 
2) Define the chemical and physical properties- such as molecular weight, size, charge, and hydro-
philicity. 
3) Select the required scale; nanotechnology or Microsystems can be selected based on medical 
needs, drug loading requirements, and level of release control. 
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This section provides a comprehensive view that will help in selecting the appropriate delivery 
method based on recent literature findings. 
2.3.1 Multi-drug therapy using a single delivery method  
Combinatorial therapy has been explored for its synergistic effect in treating drug-resistant cancers 
(Table 4).  Higher doses can be delivered inducing desired effects, however, the release profile of 
each drug usually differs, creating further challenges.  Controlled release is essential to achieve the 
required dose of each drug at the site of interest.  
Nanoparticles have been used to carry multiple drug payloads.  Multiple drugs are incorporated 
into the delivery vehicle and released in a controlled manner.  Lipid bilayer spherical vesicles, or 
liposomes, are one approach for combination drug delivery.  One example is CPX-351 liposome 
used for leukemia treatment.  This liposomal system can be loaded with cytarabine and daunorubi-
cin [60].  Another method is polymeric-nanoparticles which consist of solid polymeric cores.  The 
latter is more suitable for delivering water-insoluble drugs.  Polymer-drug conjugates have also 
been explored.  They show enhanced delivery of water-soluble molecules such as paclitaxel, dox-
orubicin (DOX), and camptothecin.  The delivery system improves the pharmacokinetics and effi-
cacy of these drugs [61]. 
Others have investigated core-shell nanoparticles for combination delivery.  For example, tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) and DOX have been co-encapsulated 
into a core-shell nanoparticle, resulting in a synergistic effect by targeting different pathways [62]. 
Nanoparticles have emerged as promising carriers for multidrug delivery.  Small molecule drugs 





Table 2.4:  Combination of treatment delivery for cancer applications. 
Delivery method Loaded drugs Target Reference  
Polymer drug conju-
gates 
Verapamil, and DOX  Leukemia [61] 
Core-shell nanoparti-
cles  
TRAIL and DOX Lung cancer  [62] 
Liposomes  cytarabine/daunorubicin 
(CPX-351) 
Acute Myeloid Leukemia [60] 
Lipid micelles  Hydrophobic inhibitor of 
transforming growth factor 
β (TGF-β), and the hydro-
philic protein interleukin-2 
Tumors and stromal cells [63] 
Liposomal hydrogel 
scaffolds  
Regenerative cells, protein, 
and  growth factor 
Implant at the target site [64] 
Co-electrospun nano-
fibers 
BSA and myoglobin Improve cellular interac-
tions, (cell adhesion, prolif-
eration, and differentiation) 
[65] 
 
be encapsulated.  The solvent selection process for these drugs is a key requirement for successful 
encapsulation of different polarity drugs [66].  This delivery method has enhanced the synergy, and 
pharmacokinetics associated with each drug [67].  Many types of nanoparticles have been explored 
for their potential in multidrug delivery.  Liposomes have been used to deliver and enhance the 
efficacy of chemotherapy pairs.  Lipid micelles have been utilized for their high drug loading ca-
pacity and tunable sizes.  Also, they have shown promising results in clinical trial phase I for a 
variety of cancers [63].  Liposomal hydrogel scaffolds have been explored for localized delivery.  
These scaffolds can be pre-designed outside the body to form its three-dimensional shape to be 
administrated locally [64].  Others have explored co-electrospun nanofibers for multidrug delivery.  
A composite system of this delivery method can be formulated for loading multiple drugs, where 
the system is composed of a mixture of different-drugs-loaded electrospun nanofibers [65].  
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2.3.2 Multi-drug therapy using multi-delivery methods  
Although several combination delivery techniques have been explored, the multi-delivery method 
has not been thoroughly addressed.  Nanocarriers, for example, have been used as a single delivery 
method for multi-drug delivery [68].  However, using multiple, different, delivery methods can 
improve the release profiles and time of administration for combination therapy.  This method re-
duces multidrug resistance in cancer cells, attributed to the optimal synergistic effect achieved by 
sequential administration of each drug.  For instance, liposomes can be combined with other types 
of nanoparticles, such as core-shell nanoparticles, to deliver two or more different drugs.  Using 
this method of delivery introduces better flexibility regarding the time of administration, and con-
trol upon the optimal effect on each drug, based on their kinetic profiles (of uptake and release).   
Nanoparticles co-administration of multiple drugs improve both the uptake and the cytotoxicity of 
the combination therapy [69].  DOX-encapsulated nanoparticles were administrated in combination 
with verapamil-encapsulated nanoparticles, inducing higher toxicity effects on NCI/ADR-RES 
cells compared to the single delivery method [70].  Administration of electrospun fibers, however, 
remains a challenge.  As nanoparticles could be administered intravenously, local administration is 
suggested for electrospun fibers.  This procedure has been explored to promote cartilage regenera-
tion [71].  However, the area of local administration of electrospun fibers for drug release remains 
nascent. 
2.4 Kinetic and parametric modeling of electrospun fibers and nanoparticles 
Electrospun fibers delivery is carried out through two main routes: 1) drug release from the fibers 
and 2) cellular uptake of the drug.  Each step includes several factors to be taken into consideration 
when designing fibers as delivery vehicles.  In the first step, the hydrophilicity/lipophilicity of the 
drug affects its diffusion and permeability as it is released from the fiber.  These parameters can be 
modeled as discussed later in this section.  The second step occurs once the drug is released (Figure 




Figure 2.4: Schematic representation of drug release and uptake. 
 
Certain enzymes or side targets cellular uptake may take place and may lead to significant depletion 
of the drug even if maximum release is reached.  Both steps should be taken into account in order 
to achieve a fully controlled delivery process.  As opposed to electrospun fibers, nanoparticles, 
such as liposomes, are not associated with release rates, but rather uptake rates.  Hence, loading 
efficienc and particle rigidity are more relevant parameters that are introduced in this section. 
Electrospun fibers have the potential to deliver various cancer drugs and have a wide range of 
applications.  It is essential to establish a release profile for the electrospun fiber, as the controlled 
release is achieved through a well-established release model.  A previous review [72] has shown 
various models associated with different types of electrospun fiber.  Both lipophilic and hydrophilic 
molecules have been released from electrospun fibers.  It was found that the structure of electrospun 
microfibers (single, co-axial, or tri-axial) has an effect on releasing hydrophilic molecules, while 
this effect is negligible when releasing lipophilic molecules [73, 74].  This is attributed to the mass 
transfer dominating process occurring in each case.  Lipophilic drugs are mainly replaced by water 
molecules resulting in a dominating partition coefficient factor (Eq. 1) [75].  This number is a 
22 
 
measure of solubility of molecules in an organic (octanol) versus aqueous (water) solution.  The 
larger the partition coefficient value, the more lipophilic the molecule.  Hydrophilic molecules, 
however, are released by a dominating diffusion factor which can be experimentally determined as 
given by Fick’s law (Eq. 2) [76].  The concentration profile can be generated experimentally, and 
the diffusion coefficient can be determined by the slope of flux versus concentration-distance gra-
dient line.  For release from single layer fibers of (1:1 of PCL and GT), the diffusion coefficient is 
generally > 10-10 m2/hour for lipophilic molecules, and < 10-10 m2/hour for hydrophilic molecules 
[73], [74]. 
𝐾𝑐 =  
𝐶𝑜𝑐𝑡𝑎𝑛𝑜𝑙
𝐶𝑤𝑎𝑡𝑒𝑟




    (2) 
Where 𝐾𝑐 is the partition coefficient, 𝐽 is diffusional flux (given in mol m
−2 s−1), 𝐶 is drug’s con-
centration, 𝐷𝑎𝑏 is the diffusion coefficient, and 𝑥 is the diffusion path length.  
Nanoparticles are also characterized by their rigidity and loading capacity.  The diffusion coeffi-
cient of nanoparticles depends on the particle’s rigidity [77].  It has been shown that soft nanopar-
ticles (10 nm) in polymeric matrices (20 nm) increases their diffusion coefficient.  Another study 
describes rigidity models for nanoparticles [78], where the stiffness factor is given by Eq. 3. 





    (3) 
where 𝐶 = √
𝐸
𝜌
 is the one-dimensional speed of sound in the solid, E is the Young’s modulus and ρ 
is the density, a and b refer to the adsorbate and the cantilever, respectively, and 𝜀 is a dimension-
less parameter.  It is shown that the stiffness coefficient for gold nanoparticles is roughly 0.03.  
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Loading efficiency and capacity, as well as kinetic studies, can be performed on nanoparticles.  A 
recent investigation of the kinetics of polymyxin B (PMB) loading onto anionic mesoporous silica 
nanoparticles (MSN) is presented in another study [79].  The loading capacity (LC) is given by Eq. 
4. 
𝐿𝐶 =
(𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑝𝑝𝑙𝑖𝑒𝑑 𝑃𝑀𝐵−𝑚𝑎𝑠𝑠 𝑜𝑓 𝑛𝑜𝑛𝑎𝑑𝑠𝑜𝑏𝑟𝑒𝑑 𝑃𝑀𝐵) 
𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑀𝑆𝑁
  (4) 
Loading capacity depends highly on the particles and drugs chemical and physical nature.  Emul-
sions, for example, result in significantly higher loading capacities compared to suspensions.  This 
is due to drug solubilizing effect by a liquid matrix of particles, compared to that of the solid crys-
talline matrix.  It has been shown that up to 50% higher loading is achieved by emulsions compared 







CONTROLLED RELEASE OF RESVERATROL, IN COMBINATION WITH SIRNA, EF-
FECT ON LEUKEMIA CELLS VIABILITY 
 
 
 3.1 Introduction 
Resveratrol gained significant attention in the early 1990s, consumption of red wine in France was 
attributed to the low incidence of cardiovascular diseases, despite higher consumption of saturated 
fat [81].  This was termed “French paradox,” and provided significant impetus to exploring resvera-
trol as a dietary supplement in cardiac and cancer therapies [82, 83].  Molecular mechanisms 
through which resveratrol mediate such interactions is explored in various disease models, includ-
ing cancer [84].  In vitro studies show that resveratrol induces apoptosis via sphingosine kinase 1 
(SphK1) inhibition, which is associated in promoting various types of cancers including CML [85], 
and prostate cancer [86].  Others have shown that resveratrol causes autophagy in K562 cells, the 
erythroleukemia cell type commonly used to study CML [87] and the formation of intracellular 
autophagosomes [88].  Resveratrol is shown to cause changes in mitochondrial activity [89] using 
tetrazolium salt-based calorimetric assays, which is reduced to formazan. 
Clinical trials performed by administering 500 mg of trans-resveratrol showed no significant side 
effects [90].  Another study with 150 mg/day of trans-resveratrol given to healthy volunteers 
showed signs of calorie restricted diet effects [91].  However, plasma levels after 30 days were in 
the nanomolar range, nearly 3 orders of magnitude less than required to cause apoptosis in cancer 
cells in vitro.  
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Rapid reduction in the bioavailability of resveratrol after systemic administration is attributed to 
various factors, including biotransformation, short half-life (1-3 hours), rapid uptake by cells, and 
lipophilic characteristics with limited solubility in water [92, 93].  Metabolism of resveratrol also 
varies from person to person due to alterations in gut-associated bacteria [94].  In order to obtain 
therapeutic levels needed for inducing apoptosis, controlled release of trans-resveratrol at the site 
of interest is necessary.  In addition, combining resveratrol with other drugs targeting other cellular 
pathways could reduce the dosage requirements [95, 96].   
Recently, electrospun fibers have emerged as ideal candidates in drug delivery systems, as they 
offer a better degree of control over the release kinetics relative to competing methods such as 
nanoparticles [97].  In particular, the formation of multilayered core-shell fibers using multiaxial 
electrospinning allows sequestering stimulants in different compartments to modulate the release 
kinetics [98].  Also, one could blend lipophilic polymers, such as poly(ε-caprolactone) (PCL), and 
hydrophilic polymers, such as gelatin (GT), in various ratios and form fibers.  These combinations 
allow encapsulation of both hydrophilic and lipophilic (or hydrophobic) drugs while providing a 
high surface to volume ratio, cell attachment, and drug loading.  These polymers are also biocom-
patible and biodegradable i.e., they can be locally implanted with the expectation of complete deg-
radation.  However, there is a lack of model-based fundamental understanding of the influence of 
such layering and polymer selection on the permeability of lipophilic drugs.  
In this regard, I first tested the combination effect of resveratrol and small interfering RNA 
(siRNA), to downregulate the fused breakpoint cluster region (BCR)-Abelson (ABL) tyrosine ki-
nase gene pathway; BCR-ABL deregulation is shown to be sufficient to sustain CML phenotype 
[99, 100].  Based on the literature reports, resveratrol [85] and siRNA [10] dosage were selected.  
Combination of resveratrol and siRNA was more effective in inducing apoptosis even at lower 
doses.  Next, I selected 40 M resveratrol and formed PCL-GT hybrid coaxial fibers using a com-
mon solvent and a previously published method [101].  I evaluated the release profile of resveratrol 
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and its effect on K562 cells.  Loading resveratrol into electrospun fibers provided a delivery method 
needed to obtain dosage levels locally.  Evaluation of permeability using resistance in series model 
showed no dependency on layering, suggesting that the rate of lipophilic drug release is less de-
pendent on various layers. 
3.2 Materials and methods 
3.2.1 Materials 
PCL (80 kDa, Mn = 80,000), Type A gelatin (porcine 300 Bloom), 2,2,2-trifluoroethanol (TFE), 
Caffeine, propidium iodide (PI) powder, sterile dimethyl sulfoxide (DMSO), and trans-resveratrol 
were purchased from Sigma-Aldrich (St. Louis, USA).  A custom-synthesized BCR-ABL siRNA 
(5′-GCAGAGUUCAAAAGCCCTT-3′), and a corresponding scrambled siRNA (5’-GCCCCAA-
GATATAGGTTCA-3’) were purchased from Integrated DNA Technologies (Coralville, IA).  An-
nexin V FITC conjugate was purchased from Thermo Fisher Scientific.  K562 cells were purchased 
from ATCC (Manassas, VA) and cultured in RPMI 1640 medium (Sigma-Aldrich, St. Louis, USA), 
2 mM Glutamine, prepared with 10% FBS obtained from ATCC (Manassas, VA).   
3.2.2 Cell culture maintenance 
K562 cells were cultured in T75 cell culture flasks following the vendor’s protocol.  In brief, cells 
were incubated in 5% CO2/95% air, at 37 C and culture medium was changed every 3 days by 
centrifuging cell suspensions for 5 minutes at 840 ×g and 4 ᵒC.  The formed cell pellet was re-
suspended in 9 mL of fresh culture medium and plated in a fresh T75 flask.  All cultures were 
routinely monitored under an EvosTM AME-i2111 Digital Inverted Microscope, and when neces-





3.2.3 Resveratrol and siRNA dosage effect in solution 
For all experiments, cells were harvested, counted using the hemocytometer, and 2×105 cells/mL 
were cultured in a 6-well plate with 2 mL of fresh media for each well.  All cell cultures were 
incubated for 72 hours prior to analysis for viability as described in cell viability section.  
Resveratrol alone: A 40 mM stock solution of resveratrol was dissolved in DMSO and stored at 4 
ᵒC until further use.  Based on a previously published report [85], samples were prepared with 0, 
10, 20, 40, 80, and 160 µM resveratrol concentrations.  Zero concentration condition had DMSO 
equivalent to that present in 160 µM resveratrol condition, added directly.  
siRNA alone:  A stock solution of 625 nM siRNA in 150 mM NaCl was prepared.  Based on a 
previously published report [10], samples were prepared with 0, 12, 24, 36, 48, and 60 nM range 
of siRNA concentration.  Zero concentration condition contained NaCl equivalent to that present 
in 60 nM siRNA condition, was added directly.  Scrambled siRNA was tested at 36 nM concentra-
tion. 
Resveratrol and siRNA combination experiments: Three conditions were used based on a factorial 
design of experimental approach:  
i) 40 µM resveratrol and 36 nM siRNA.   
ii) mid-point concentrations using 20 µM resveratrol, and 18 nM siRNA  
iii) Control samples were prepared by directly adding DMSO and NaCl solution equivalent to that 
present in 40 M resveratrol solution and 36 nM siRNA solution.  
3.2.4 Cell viability analysis 
After various incubation times, cells were centrifuged at 840 ×g for 5 minutes, and washed with 
phosphate buffer solution (PBS, 7.2 pH, prepared in-house using 8 g NaCl, 0.2 g KCl, 0.2 g 
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KH2PO4, and 2.17 g Na2HPO4-7H2O in 975 mL DI water) with 0.1% BSA (1 mL for every 2×10
5 
cells).  Then cells were stained with Annexin V buffer, using the vendor’s protocol.  In brief, cells 
were centrifuged again and washed with Annexin V buffer solution (140 mM NaCl, 4 mM KCl, 
0.75 mM MgCl2 and 10 mM HEPES in DI water).  Cells were centrifuged and re-suspended in 
Annexin V buffer solution (50 µL per 105 cells).  Then, 1 µL per105 cells of Annexin V FITC 
conjugate were added and incubated on ice for 15 minutes.  Also, 50 µL per 105 cells of Annexin 
V buffer was added, followed by 4 µL of PI (100 mg/L), and then incubated in ice for another 15 
minutes. Cells were washed with 500 µL of Annexin V buffer solution, and the suspension was 
then discarded.  The cells pellet was re-suspended in 500 µL of Annexin V buffer solution and 
incubated on ice for 10 minutes before samples were analyzed using a FACSCalibur (Becton Dick-
inson, San Jose, CA) flow cytometer.  Unstained samples and individually stained samples were 
used as controls.  Obtained data for each sample was plotted in dot plots, where the cell populations 
separate into at least two groups: live cells with a low level of fluorescence and non-viable cells 
with substantially higher fluorescence intensity.  Dead cells were labeled with both the PI and An-
nexin V conjugate.  Based on this information, percentages of dead cells were obtained using a 
standard quadrant analysis.   
3.2.5 Stability of resveratrol in culture medium 
In order to understand the changes in resveratrol concentration during 3-day incubation, cell culture 
experiments were performed in 6-well plates in two groups: i) with 2×105 K562 cells/mL cells and 
ii) without cells, but with the same amount of cell culture medium.  In both groups, 40 M resvera-
trol was added to the culture medium using the same stock solution used in viability.  All conditions 
were incubated in 5% CO2, and 37 C.  From each group, the culture medium was collected every 
24 hours and analyzed for resveratrol content using HPLC.  Samples with cells were centrifuged at 
840×g to remove the cells.  Resveratrol concentration (released drug) was measured using an 
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HPLC, using a previously reported method with minor modifications [102].  In brief, a 4.6 × 150 
mm C18 column (Acclaim, National Scientific Rockwood, TN) was used, with a 5 µm particle 
diameter, and a 120 Å pore size.  A 4.6 × 10 mm C18 guard column with a 5 µm particle diameter 
(Acclaim, National Scientific Rockwood, TN Guard Cartridge, and Cartridge Holder) was also 
used.  The mobile phase consisting of 30% acetonitrile, and 70% 25 mM sodium phosphate mono-
basic at pH 4.0 was prepared using HPLC grade chemicals.  Mobile phase flow rate was set at 4 
mL/min, and the injection volume was set to 25 µL.  Caffeine was used as the internal standard.  
Resveratrol samples were dissolved in the mobile phase, while the internal standard was dissolved 
in methanol, and a ratio of 2:1 of resveratrol to internal standard was used.  HPLC system was 
controlled using Chromeleon software (version 6.8 Dionex Sunnyvale, CA).  A calibration curve 
was also prepared (in the range of 0 to 160 M) similarly, using known resveratrol concentrations.   
For each group, at least three samples were used.  Obtained data at different time points were plotted 
as an average (± standard deviation) and curve fitted to understand the kinetic behavior.  
3.2.6 Preparation of electrospun fibers with resveratrol 
Based on prior studies [103], 10 and 17 wt% concentrations of PCL and GT, respectively, were 
dissolved independently in the common TFE solvent.  All solutions were stirred for 24 hours.  Then 
1:1 (volume basis) ratio of PCL and GT solutions were mixed together prior to electrospinning.  
Electrospinning was performed using the methodology described previously, with minor modifi-
cations [101].  In brief, setup (Figure 3.1a) consisted of two syringe pumps (74900 series, Cole-
Parmer, Vernon Hills, IL), coaxial needles, syringes, high voltage power supply (ES30P-5W/DAM, 
Gamma High Voltage Research, Ormond Beach, FL), earth grounding, and a collection mandrel.  
Solutions were loaded into a 10 mL syringe and fed to a spinneret held at 17 kV.  Core needle inner 
diameter was 0.4 mm while the shell inner diameter was 1.00 mm.  Syringes were connected to the 
spinneret via 30 cm long 20-gauge PTFE tubing (Sigma Aldrich, St. Louis, MO).  Core solution 
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was pumped independently at 1 mL/h, while the shell solution was pumped at 3 mL/h.  Electro-
spinning was performed in low humid conditions (<50%) at 22 C.  The distance between the col-
lector plate and the spinneret was 15 cm.  A collector plate made of aluminum foil wrapped around 
a 6-well tissue culture plate was used as described previously [104].  In order to improve the han-
dling of the prepared structures, circular voids were created in the collector plate that corresponded 
to a diameter suitable to fit a 6-well plate.  The amount of resveratrol added to the fiber preparation 
was based on correlating the well area (35 mm diameter) to the volume of resveratrol added.  These 
calculations showed that 2 µL of 40 mM resveratrol stock solution was needed for each well, i.e., 
12 µL per 2 mL of fiber solution when collected on a 6-well plate.  Since fibers were deposited in 
areas around the circular void (~ 38% of the total solution), the amount of resveratrol added was 
proportionally increased.  Hence, 16.56 µL of 40 mM resveratrol stock solution was loaded into 2 
mL of core fiber solutions.  
Then setup was configured to form fibers in four configurations as follows:  
i) Control: With an outer PCL-GT and an inner core of PCL-GT without resveratrol (Figure 3.1b) 
ii) Single: Only one stream of PCL-GT with resveratrol (Figure 3.1c) 
iii) Co-Single: With an outer PCL-GT and an inner core of PCL-GT containing resveratrol, provid-
ing a single phase (Figure 3.1d), but loading resveratrol in the core increased the distance the drug 
has to travel.   
iv) Co-PCL: With an outer PCL-GT and an inner core of PCL containing resveratrol (Figure 3.1e), 
as PCL core allows evaluating resveratrol release from a hydrophobic polymer, which is compatible 




Figure 3.1: Resveratrol loaded electrospun fibers formation (a) Schematic of coaxial electro-
spinning showing various components.  (b) Control configuration showing coaxial PCL-GT fiber 
with PCL-GT inner core and no resveratrol schematic and corresponding micrograph.  (c) Single 
PCL-GT fiber with resveratrol schematic and corresponding micrograph.  (d) Coaxial PCL-GT 
fiber with PCL-GT inner core with resveratrol schematic and corresponding micrograph. (e) Coax-
ial PCL-GT fiber with PCL inner core with resveratrol schematic and corresponding micrograph.  
Small circles within the inner core represent resveratrol. 
3.2.7 Fiber characterization 
Dry fibers from all configurations were analyzed using a scanning electron microscope (SEM) (Jeol 
JOEL 6360USA Inc., Peabody, MA), similar to a previous publication [104].  In brief, samples 
were cut into 2-mm strips, attached to an aluminum stub using double-sided conductive tape, and 
sputter-coated with gold for 1 min to make the samples conductive.  Samples were visualized at 24 
kV accelerating voltage, and 1000× magnification.  Using the digital micrographs in ImageJ, fiber 
size and porosity were analyzed, similar to a previous publication [101]. 
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In order to determine the initial loading of resveratrol, it was selectively extracted from each fiber 
configuration using 30% acetonitrile, and 70% 25 mM sodium phosphate mono-basic at pH 4.0.  
Samples were incubated for 48 hours at room temperature, where the containers were completely 
wrapped using parafilm.  Samples were collected while ensuring there were no fiber components 
prior to analysis using HPLC as described above.   
3.2.8 In vitro release of resveratrol 
PCL-GT electrospun fibers from all four configurations were cut to the circular area (35 mm in 
diameter) formed at each well of the void collector plate.  Fibers were sterilized before introduction 
to cell culture using the following process: 2 mL of 100% ethanol was added to each well for 25 
minutes.  Ethanol was removed, sterile PBS was added for 20 minutes, which was replaced by 2 
mL of fresh medium.  Then, the medium was removed, and fibers were kept under UV for 1 hour 
inside a biosafety cabinet.  Then, 2 mL of 2×105 K562 cells/mL solution was added to each well 
and incubated in 5% CO2, and 37 C.  After 1, 4, 9, 24, 26, 48, 72 and 96 hours of incubation, 25 
µL samples were collected from each condition.  Each sample was centrifuged at 840×g to remove 
the cells, resveratrol concentration was determined using the HPLC method as described above.  
For each group, at least three samples were used.  Obtained data at different incubation times were 
plotted as an average (± standard deviation) and curve fitted to understand release behavior.   
In order to determine cell viability, additional experiments were performed where they were termi-
nated at day 3, day 5 and day 8.  For each day, at least three samples were used.  Cells were collected 
at these time points and viability was determined using Annexin V and PI staining as described 
above.   
Cell cultures were also performed using fibers and siRNA at 36 nM concentration added directly 
to the cell culture.  These cultures were terminated at day 3.  Cells were collected at these time 
points and viability was determined using Annexin V and PI staining as described above 
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The cell-containing samples were fixed in 3.7% formaldehyde for 30 min at room temperature, 
washed with ethanol, and stored in the desiccator for 48 hours, prior to sputter coating with gold at 
40 mA for SEM analysis.  
3.2.9 Statistical Analysis 
All experiments were repeated three or more times.  Average values along with standard deviation 
were calculated.  Significant differences between two groups were evaluated using a one-way anal-
ysis of variance (ANOVA) with a 98% confidence interval.  When P < 0.02, differences were con-
sidered to be statistically significant. 
3.2.10 Modeling resveratrol permeability in PCL-GT fibers 
In order to determine the permeability of resveratrol through different layers of coaxial PCL-GT 
fibers, the model described in the previous publication [101] was used with minor modifications.  
In brief, based on model studies using the Korsmeyer-Peppas power-law model [105, 106, 107], 






(𝐶𝑀𝑎𝑡𝑟𝑖𝑥 − 𝐶𝑅𝑒𝑠,0)   (5) 
where 𝑆 is the total surface area of the matrix (7479 mm2), and 𝑉 is the total volume (2000 mm3) 
of the RPMI medium used to incubate the matrix, 𝐶𝑀𝑎𝑡𝑟𝑖𝑥  is the resveratrol concentration in the 
matrix, and 𝐶𝑅𝑒𝑠,0 is the actual resveratrol concentration in the solution prior to decay.  In order to 
calculate 𝐶𝑀𝑎𝑡𝑟𝑖𝑥 , volume of solids in the matrix was calculated using the fiber fraction () and the 
sample volume.  Then, 𝐶𝑀𝑎𝑡𝑟𝑖𝑥  was obtained by dividing resveratrol content by the volume of sol-
ids.   









       (6)  
From the obtained concentrations at various times, ln (1 −
𝐶𝑅𝑒𝑠,0
𝐶𝑀𝑎𝑡𝑟𝑖𝑥
) was calculated.  Using a linear 
fit, overall permeability (m/h) for each configuration was calculated based on the slope value.  In 
order to test the effectiveness of multiple layers on permeability, overall resistance (inverse of over-
all permeability) to the transport of resveratrol can be considered as the sum of the resistances 










   (7) 
Assuming that the Permeability of single PCL/GT fiber remains the same in the outer sheath in 
coaxial fibers as the concentrations of polymers and flow rates were identical, the resistance of the 
inner core was calculated for different configurations. 
3.3 Results 
3.3.1 Effect of resveratrol and siRNA on K562 cells in cell culture medium 
Based on literature reports regarding the effect of resveratrol concentration added directly to the 
cell culture medium [85], first I investigated that effect on K562 cells viability.  These results (Fig-
ure 3.2a) showed that when resveratrol is added directly to the cell culture medium, it induces 
K562 cell death in a dose-dependent manner, in agreement with published reports [85].  However, 
MTT assay was used in that study, rather than Annexin V and PI.  Cell death can be caused by 
either apoptosis or necrosis (death due to cell damage).  Annexin V binds to the outer membrane 
of the apoptotic cells and to the inner membrane of necrotic cells.  In contrast, PI binds to the 
nucleus of necrotic cells only as it cannot permeate through an intact cell wall.  From Annexin V 
staining, 50.35(±5.88)% of cells were non-viable with resveratrol concentration of 40 µM.  All 
cultures showed a significantly higher percentage of non-viable cells relative to control (with 
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DMSO), suggesting that the observed cell death is not due to DMSO solvent used in resveratrol.  
Both Annexin V and PI stained populations showed similar percentages, suggesting that cell death 
is primarily mediated via necrosis when directly treated with resveratrol.  To my knowledge, the 
difference between apoptotic and necrotic effects of resveratrol on K562 cell line has not been 
reported.  
Using formazan reduction assay, siRNA targeting BCR-ABL pathway is shown to induce K562 
cell death when added directly to the culture medium [10].  Similar results were observed with 
Annexin V staining in a dose-dependent manner.  These were significantly higher than the control 
sample, suggesting that these interactions are not due to NaCl present in the buffer used for siRNA.  
Further, the presence of scrambled siRNA showed significantly lower non-viable cell percentages 
at similar concentrations, confirming the specificity of the siRNA.  However, PI stained non-viable 
cells were significantly lower than the Annexin V stained population (Figure 3.2b), suggesting that 
siRNA induced cell death is primarily mediated by apoptosis.   
In order to understand whether a combination of resveratrol and siRNA act synergistically or an-
tagonistically, cells were exposed to a combination of 40 µM resveratrol and 36 nM siRNA.  These 
results (Figure 3.2c) showed that the combination was more potent than the highest concentration 
of siRNA, and nearly that of the highest concentration of resveratrol.  These increases are not due 
to the DMSO and NaCl as the control samples showed significantly less non-viable cells.  Com-
bining both molecules had an additive effect on cell death; 72 (±2.9) % cells (25 (±1.8) % mid-
point) were apoptotic and/or necrotic under these conditions.  When both siRNA and resveratrol 
were added together, the necrosis level dropped, compared to that observed when using individual 
drugs separately (indicated by PI stain).  Thus, apoptosis mechanism could be triggered when using 
combination therapy.  By inducing necrosis, the internal compartments of the cell spread out af-
fecting the surrounding environment, hence, inducing apoptosis is more desirable.  
36 
 
In order to optimize the concentrations of resveratrol and siRNA on apoptosis, experiments were 
designed via 23 full-factorial Central Composite Design, in which three experimental levels (i.e., 
concentrations) were tested for each factor (i.e., the resveratrol and siRNA).  A multiple linear 
regression model was fitted to the experimentally obtained non-viable data points using the regres-
sion function in Microsoft Excel.  A seven-parameter model was used as shown in Eq. 8: 
𝑁𝑉𝐾562 =  𝛼0 + 𝛼1𝐶𝑅𝑒𝑠 + 𝛼2𝐶𝑠𝑖𝑅𝑁𝐴 + 𝛼3𝐶𝑅𝑒𝑠
2 + 𝛼4𝐶𝑅𝑒𝑠
2𝐶𝑠𝑖𝑅𝑁𝐴        (8) 
Where 𝑁𝑉𝐾562 is non-viable K562 cell count, the 𝛼 parameters are the regression coefficients es-
timated from the factorial design, 𝐶𝑅𝑒𝑠 and 𝐶𝑠𝑖𝑅𝑁𝐴, are resveratrol and siRNA concentration in me-
dium, respectively.  Using MS Excel output, a relation between non-viable cells percentage and 
the concentrations of resveratrol and siRNA was found to be as shown in Eq. 9:  
𝑁𝑉𝐾562 =  14.31 + 0.62 𝐶𝑅𝑒𝑠 + 0.83 𝐶𝑠𝑖𝑅𝑁𝐴 − 4.65 × 10
−3 𝐶𝑅𝑒𝑠
2 + 1.31 × 10−4𝐶𝑅𝑒𝑠
2𝐶𝑠𝑖𝑅𝑁𝐴  
                 (9) 
Using Eq. 9, a surface plot showing the effect of resveratrol concentration and siRNA concentration 
was generated (Figure 3.2d).  The intent was to understand the required dosages of resveratrol and 
siRNA to obtain 100% non-viable cells.  The surface plot shows several combinations of resveratrol 
and siRNA concentrations.  Predicted values using the optimization equation were evaluated using 
several experimental measurements.  These results showed 5 to 10% error in model predicated non-




Figure 3.2: Influence of resveratrol and siRNA on K562 cell viability after 72 hours. (a) Effect 
of resveratrol concentration.  Control corresponds to cell culture without resveratrol but with 
DMSO equivalent to that in 160 M resveratrol (b) Effect of siRNA concentration.  Circular sym-
bols correspond to the scrambled siRNA and control corresponds to cell culture without siRNA but 
with NaCl present in 60 nM siRNA concentration. (c) Effect of combination of resveratrol and 
siRNA.  Control corresponds to cell culture with DMSO corresponding to that present in 40 M 
resveratrol and NaCl present in 36 nM siRNA concentration. (d) Surface plot obtained using the 
factorial design of experiments equation showing the dosages of combination therapy need to ob-
tain various level of non-viable cell percentage. 
 
In order to confirm cell death via different approaches, digital micrographs were acquired during 
the culture duration of 3 days (Figure 3.3).  These results showed the presence of necrotic cells in 
resveratrol-containing cultures, indicated by cell membrane damage, and cell content leakage.  
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Smaller fragments were formed replacing the circular shaped cells indicating apoptosis.  More im-
portantly, the number of cells was significantly less in these cultures, relative to cultures not treated 
with resveratrol (control) but containing a similar amount of DMSO.  The latter showed a signifi-
cantly higher number of K562 cells.  This confirmed cell death caused by resveratrol. 
 
Figure 3.3: Effect of resveratrol on K562 cell morphology.  Micrographs were taken every 24 
hours, in both with 40 M resveratrol and without resveratrol, with the same amount of NaCl.  
 
3.3.2 Fate of resveratrol in cell culture medium 
In order to understand the fate of resveratrol during the 3-day cell culture duration, samples were 
analyzed using HPLC.  A calibration curve was developed (Figure 3.4a) using the internal standard 
caffeine.  In the presence of K562 cells, resveratrol concentration showed a linear reduction (Figure 
3.4b).  Resveratrol was not detectable in a 72-hour sample.  In order to predict the depletion time, 
the linear fit equation was extrapolated (dashed line) to determine the x-intercept, the required time 
to reach zero concentration.  This gave a value of 70.4 hours, confirming the observed complete 
depletion of resveratrol at 72 hr.   
Since drug clearance typically follows a non-linear decay in a single compartment such as cell 
cultures, a linear depletion of resveratrol could be due to the diffusion of resveratrol into the cells 
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i.e., direct uptake by cells.  Others have shown that resveratrol uptake by K562 cells is mediated 
via binding to lipoproteins and albumin found in cell culture medium [108].  In order to understand 
the stability of resveratrol in the cell culture environment, experiments were performed in the ab-
sence of cells.  These results showed an exponential decay curve, much slower than in the presence 
of cells (Figure 3.4c).  To find the decay rate, 𝑘𝐷 , resveratrol concentration at different points in 
time 𝑡, was related to the initial concentration 𝐶𝑅𝑒𝑠,0 (when 𝑡 = 0), using a first order exponential 
decay rate as shown in Eq. 10: 
𝐶𝑅𝑒𝑠
𝐶𝑅𝑒𝑠,0
= 𝑒−𝑘𝐷𝑡      (10) 
 
Figure 3.4: Resveratrol characterization and stability in the medium.  (a) Calibration curve 
using HPLC.  (b) Resveratrol concentration change in cultures with and without K562 cells incu-
bated at 37 C and 5% CO2.  Values are plotted as a fraction of the initial dosage Cres,0 of 40 M 
resveratrol.  The dashed line corresponds to the extrapolated trend line obtained using the shown 
linear equation.  
 
Experimental data were fitted with an exponential function to obtain 𝑘𝐷 values.  Using the 𝑘𝐷  value 





, the half-life of resveratrol in medium the was calculated to be 89.6 hours 
in the cell culture, much longer than that reported in the plasma [92].  These differences could 
40 
 
further explain the lack of achieving a high concentration of resveratrol even with 500 mg dosage 
per day in vivo [93]. 
 
3.3.3 Resveratrol loaded fibers characteristics 
Based on the stability of directly added resveratrol in the cell culture medium, I questioned the 
possibility of encapsulating resveratrol in PCL-GT electrospun fibers.  Since these fibers have to 
interact with cells, all formed fibers had the same PCL-GT outer layer, in order to eliminate differ-
ent cell-polymer interactions at the surface.  However, resveratrol is a lipophilic molecule and re-
quires appropriate polymer selection for uniform distribution.  Hence, two inner core conditions 
were selected in co-axial fibers: i) inner hydrophobic PCL layer with resveratrol and ii) inner PCL-
GT layer with resveratrol providing a continuous phase in the fiber which could minimize interfa-
cial resistance during the transfer of resveratrol while providing a medium for uniform distribution 
of resveratrol.  Since hydrophilic GT environment is not compatible with loading lipophilic resvera-
trol, I did not consider forming coaxial fibers with PCL-GT and GT as the inner core.  In order to 
compare the effect of controlled release of resveratrol, a 40 M concentration of resveratrol was 
used in forming the electrospun fibers.   
These results showed successful formation of fibers in all these configurations, without any diffi-
culty.  Analyzing SEM micrographs (Figure 3.1b-e) showed no beaded fibers, confirming the sta-
bility of the electrospinning jet.  Also, the surface of the fibers appeared to be smooth, without any 
particulate structures on single fibers, suggesting no phase separation of resveratrol due to compat-
ibility issues between resveratrol and the PCL-GT.  It has been shown that GT is uniformly distrib-
uted within the fiber and it is stable for more than two weeks [101].  Similar to previous results, all 
configurations produced fibers in microsize range suggesting process parameters and solution pa-
rameters are adequate to form PCL-GT fibers with resveratrol [101].  Co-single coaxial fibers had 
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larger diameters compared to single fiber, due to additional layers and an increase in the volume of 
the spinning solution.  Random analysis of micrographs collected using SEM via an image analysis 
software confirmed that the fiber diameter, porosity, and matrix thickness were identical to that 
reported in the literature [101].  Hence, the addition of a small amount of resveratrol did not alter 
the fiber size and matrix characteristics relative to previous analysis.   
3.3.4 Influence of fiber configuration on the resveratrol release profile  
In order to understand the loading efficiency of resveratrol in different fiber configurations, I eval-
uated the amount of resveratrol in fresh fibers.  All three fiber configurations demonstrated a very 
high loading efficiency of 88.3 (±8.06) %, 81.8 (±1.47) %, and 76.9 (±4.55) % (Figure 3.5a), for 
single fiber, Co-single phase, and Co-PCL, respectively. 
The intent of forming different configurations was to test the possibility of controlled release of 
resveratrol and increase its concentration beyond 3 days.  The amount of resveratrol in the culture 
medium was evaluated.  These results showed a release profile saturating at day 5 (Figure 3.5b).  
The values provided were based on resveratrol available in the cell culture medium in the presence 
of cells.  They did not account for the decay or the uptake of resveratrol by cells during the incu-
bation time.  Without those corrections, nearly 95% of resveratrol was present after 100 hours from 
single fibers.  Coaxial fibers in both configurations showed similar release profiles, suggesting no 
significant influence of the outer sheath layer.  This suggests that the release of resveratrol is inde-
pendent of fiber’s configuration.   
In order to understand this, the permeability of resveratrol was calculated using resistance in series 
model [101].  Calculated permeability values for all three configurations provide similar permea-
bility values (Figure 3.5c); where single fiber matrix determined permeability was 10.6 m/h.  Alt-
hough resveratrol (MW = 228.25 g/mol) is nearly half the molecular weight as doxycycline (MW 
= 444.43 g/mol), obtained permeability was similar in single fibers [101].  Permeability of fibers 
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or membranes is a function of both lipophilicity and diffusivity.  Hence, resveratrol release process 
may be significantly dependent on its lipophilicity, as water molecules diffuse through the fiber 
layers and replace the drug, forcing it to be released.   
 
Figure 3.5: Resveratrol loaded electrospun fibers.  (a) Comparison of drug loading in different 
configurations.  The dashed line corresponds to the initial concentration of resveratrol added to the 
polymer solution.  (b) Resveratrol release behavior from various fibers.  (c) Effect of fiber config-
uration on the permeability constant.  
3.3.5. Effect of resveratrol loaded fibers on cell death 
In order to understand the bioactivity of resveratrol released from the electrospun PCL-GT fibers, 
K562 cell viability was analyzed for three, five, and eight days.  These results showed a time-
dependent increase in the level of apoptosis indicated by Annexin V (Figure 3.6a) staining, corre-
lating to the release profile.  Further, the control group containing co-single fibers but without 
resveratrol showed no significant changes during the incubation time.  This suggested that the re-
leased resveratrol from fibers is bioactive and the observed non-viability is not due to solvents used 
in fiber generation or sterilization.  More importantly, the apoptotic level at day 8 was similar to 
that observed at day 3 when 40 M resveratrol was added directly to the cell culture medium.  One 
needs to extend the studies to ten days to see whether increased cell death mimics day 5 results 
when 40 M resveratrol was added directly to the cell culture medium.  When PI staining results 
were evaluated, day 3 results were similar to that of the control group containing co-single fibers 
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with the release profile (Figure 3.6b).  However, necrosis was moderately lower.  This could be 
due to the controlled release process, which enhanced the level of apoptosis.   
In order to understand further, cell cultures were observed at different days during the culture time. 
On day 8, apoptotic bodies were observed (Figure 3.6c) in all three fiber configurations compared 
to the control sample.  Apoptotic bodies were more prevalent than vacuoles formation, indicating 
lower levels of autophagy.  Using the controlled delivery system, the level of apoptosis significantly 
increases compared to that of necrosis.  Since cellular uptake is diffusion i.e., concentration-de-
pendent, it is possible that the controlled release could decrease the uptake of resveratrol by the 
cells, compared to direct introduction to the cell culture medium due to reduced concentration gra-
dient.  Hypothetically, the controlled release provides a specific concentration of the drug associ-
ated with apoptosis, over a certain period, triggering the process.  In comparison, introducing the 
same total concentration to the cell medium caused necrosis.   
 
Figure 3.6: Influence of fiber configuration on resveratrol-mediated K562 cells death. (a) An-
nexin V stained non-viable cells.  (b) PI stained necrotic cells.  Condition “Free” corresponds to 40 
M resveratrol added directly to the medium. Condition “control” corresponds to Co-Single fibers 
without resveratrol.  * represents statistical significance with p < 0.02 between Annexin V and PI 
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stained cell populations in the same fiber configuration for the same day. $ represents statistical 
significance with p < 0.02 between experiments with and without siRNA in the same fiber config-
uration stained with Annexin V. (c) Micrographs showing the morphology of K562 cells in pres-
ence of fibers in culture after eight days of incubation. 
 
In order to understand changes in fiber stability during the incubation time, samples were analyzed 
via SEM after 3 and 5 days of incubation.  Comparison of results in the presence and absence of 
resveratrol showed no significant differences between configurations (Figure 3.7).  However, sin-
gle fiber and Co-PCL configuration had more cells trapped in the fibers, which increased over time, 
compared to Co-single phase fibers.  This could be attributed to the nanostructures that formed in 
single fiber and Co-PCL configurations.  This could affect the determination of cell viability using 
flow cytometry since certain cell count is lost due to cell entrapment.  
 
Figure 3.7: Morphology of fibers after incubation for 3 days and 5 days with K562 cells.  Mi-
crographs were obtained after drying the samples from respective time periods.  Also present are 
some of the cells trapped within the fibers.   
 
3.3.6 Effect of siRNA in the presence of resveratrol-containing fibers 
Additional experiments were performed by adding siRNA to the culture medium, where PCL-GT 
fibers were present.  Interestingly, there seemed to some interaction between the siRNA and fibers.  
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In the control group (Figure 3.8), where no resveratrol was present, there was a significant reduc-
tion in non-viable cells in comparison to 36 nM siRNA concentration added directly to the cell 
culture medium (Figure 3.2b); at 36 nM siRNA alone, 46.3% non-viable cells were observed which 
reduced to 21.5% in the presence of fibers.  A similar reduction was also observed with PI staining; 
at 36 nM siRNA alone, necrotic cells were 29.5%, which reduced to 16.4% in presence of PCL-GT 
co-single fibers.  In the presence of resveratrol-containing fibers, these numbers decreased further.  
In order to realize a similar combination effect, developing a delivery system for siRNA to ensure 
controlled release needs to be studied.  Furthermore, one could investigate the targeted delivery of 


























































Figure 3.8:  Influence of a combination of 36 nM siRNA added to medium and fibers contain-
ing resveratrol on K562 cells on day 3. (a) Annexin V stained non-viable cells. (b) PI stained 
necrotic cells.  Condition “Free” corresponds to 40 M resveratrol and 36 nM siRNA added directly 
to the medium.  Condition “control” corresponds to 36 nM siRNA with the Co-Single fibers without 






Based on many studies showing the protective effects of resveratrol, clinical trials have been per-
formed [90] and further explored in cancer therapy [82, 83].  However, these results have shown 
less success of resveratrol when systemically administered due to the pharmacokinetic characteris-
tics of resveratrol.  In an attempt to enhance the bioavailability of resveratrol, controlled release of 
resveratrol has been investigated [109].  Controlled release of resveratrol from electrospun PCL-
GT fibers seems to be more effective in loading and controlled release in relation to other delivery 
systems.  Using chitosan-based nanoparticles, in vitro release of resveratrol was studied at pH 6.8 
for eight hours [110].  Adherent fibroblasts non-viability showed only resveratrol to be better at 
tested doses.  Controlled release of resveratrol was tested using lecithin mixed micelles [111], 
where the release of resveratrol was extended to 24 h.  Some reported higher loading efficiency 
using mPEG-poly(-caprolactone)-based nanoparticles, and cumulative controlled release was ex-
tended to five days [112].  Others have explored forming resveratrol containing core-shell nano-
particles to improve the bioavailability [110, 113].  Hence, my delivery method using PCL-GT 
blends, to encapsulate higher loading of resveratrol, offers a new approach for delivering hydro-
phobic drugs for a longer duration. 
In coaxial PCL-GT electrospun fibers, the inner core can be chosen based on the properties of the 
therapeutic agent.  Previously, hydrophilic doxycycline was delivered using GT and PCL-GT inner 
cores, while lipophilic resveratrol can be delivered using PCL and PCL-GT inner cores.  Blended 
hydrophilic GT with hydrophobic PCL helps load a broad range of components.  The encapsulation 
efficiency of lipophilic drugs after electrospinning in hydrophobic polymers is known to be signif-
icantly higher [114], similar to my observation.  Further, electrospun PCL-GT fibers have also been 
investigated for their biodegradability and biocompatibility [115].  Hence, PCL-GT fibers can be 
locally administrated into the bone marrow to achieve a local therapeutic concentration of resvera-
trol.  Similar ibuprofen-loaded polylactic-co-glycolic acid (PLGA) biodegradable fibers have been 
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explored in reducing fibrosis after lumbar laminectomy in a local implantation model [116].  In 
order to better understand the utility of such fibrous mats, further studies are required using animal 
models.  
There have been many studies showing the usage of electrospun fibers in local delivery with many 
coaxial configurations [98].  However, the modeling of the release profile from such fibers is lim-
ited to understanding whether the release behavior is dictated by Fickian diffusion.  In this regard, 
I extended such modeling to understand the changes in the permeability of the drug with various 
combinations of the polymeric blends.  Permeability of lipophilic resveratrol was not controlled by 
the configuration of electrospun fibers, unlike that observed with hydrophilic doxycycline [101].  
Others have reported similar results in co-axial fibers using poly(butylene succinate) with lipophilic 
curcumin [117].  Curcumin release from different configurations into ethanol showed no depend-
ency on structures, consistent with my observation in this Chapter.  This suggests that the partition 
coefficient may be a dominant factor, rather than diffusion in the controlled release of lipophilic 
drugs.  In this Chapter, the mass ratio of PCL and GT were similar and as they both have similar 
molecular weight, the molecular ratio is, also similar.  In order to understand the changes in the 
partition coefficients, one has to test the effect of altering the ratio of PCL-GT in the outer sheath.  
Determining the permeability values of individual layers helps in correlating the diffusion in order 
to understand the effect of partition coefficient.  Such an analysis would be valuable in tuning the 
release profile of other lipophilic therapeutic agents.   
This study explored combining resveratrol and siRNA to induce 100% non-viability of cancer cells.  
Using a factorial design approach, I estimated the dosages required of both drugs when adminis-
tered into the cell culture medium.  However, the influence of siRNA in the presence of PCL-GT 
fibers was reduced, probably due to non-specific interactions between the naked siRNA and the 
fibers.  In addition, endogenous characteristics of siRNA such as negative charge, rigid structure, 
size, and stability, make passive diffusion through cell membrane quite challenging.  Some have 
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addressed this challenge by delivering siRNA using endocytosis with liposomes [34].  Ligand-
targeted liposomes have shown great potential in many novel delivery systems, with high in vivo 
response due to their active targeting, increased stealth, and controlled drug release.  PEG coating 
(to overcome rapid clearance from circulation) and ligand attachment (to avoid non-specific bind-
ing) are specifically important to overcome the challenges associated with liposomal delivery sys-
tems [42].  Based on the type of cancer, certain types of ligands provide higher binding efficiency 
and many fold decrease in IC50 value compared to non-targeted liposomes.  Holo-transferrin con-
taining liposomes show enhanced intracellular uptake compared to free Bcl-2-siRNA in vivo and 
decreased IC50 (treated with doxorubicin in vitro) values.  Holo-transferrin attachment also showed 
improved tumor growth inhibition, and higher survival time compared to the non-targeted liposo-
mal system [42].  Chapter IV provides a detailed study of the combined delivery system of electro-
spun microfibers and holo-transferrin-conjugated-PEG liposomes (referred to as liposomes in this 





ASSESSMENT OF THE COMBINATION TREATMENT OF LEUKEMIA CELLS, USING 
SIRNA-LOADED LIPOSOMES, AND CONTROLLED RELEASE OF RESVERATROL 
4.1 Introduction 
To eliminate side effect, and drug interaction, the combined delivery system has gained my atten-
tion towards achieving the second aim of this project.  Small interfering RNAs (siRNAs), which 
are 20-25 base pairs in length, have been shown to be very effective in silencing targeted genes 
since the first demonstration in 2010 [6].  siRNA’s half-life is approximately 24 h [7], which ne-
cessitates a higher dosage.  Although local administration of siRNA has limited side effects, sys-
temic administration exacerbates side effects, which lead to early termination of clinical trials 
[118].  siRNA endogenous characteristics such as negative charge, rigid structure, size, and stabil-
ity, make passive diffusion through cell membrane quite challenging [119].  To address this chal-
lenge, endocytosis becomes an effective mechanism of delivery that can be achieved using lipid-
based nanoparticles [34].  In order to improve safety and minimize the dosage of drugs, targeting 
based on increased expression of certain receptors in cancer cells has been a strategy.   
Leukemia-specific siRNA has been investigated to downregulate the fused breakpoint cluster re-
gion (BCR)-Abelson (ABL) tyrosine kinase gene pathway.  This silencing technique is shown to 
be sufficient to sustain CML phenotype [120].  As mentioned earlier, ligand-targeted liposomes 
with PEG coating (to overcome rapid clearance from circulation) and holo-transferrin attachment 




In this chapter, I discussed in detail my evaluation of the effect of two different drug delivery de-
vices on inducing cancer cell death selectively.  Treatment with resveratrol or siRNA increases 
response sensitivity in cancer cells [121].  The combination of these two drugs enhanced the effec-
tiveness and drug resistance in cancer cells.  I hypothesize that combining two drugs using two 
different drug delivery devices leads to an improved therapeutic effect of each drug with reduced 
dosage.  To test the hypothesis, I used a model study comprising; i) delivering resveratrol using 
microfibers, and ii) delivering siRNA targeting BCR-ABL expression using liposomes.  This al-
lows the controlled administration of each drug in a timely manner.  In addition, I used a co-culture 
system comprised of K562 cells and HUVECs, which also helps understand the device-blood vessel 
interactions.  I show that resveratrol released from PCL-GT electrospun fibers and delayed siRNA 
delivered through holo-transferrin conjugated PEG-liposome induces 92.7 (±2) % non-viability by 
day 8.  The use of co-cultures introduces a unique tool to estimate treatment effect on healthy cells 
as well as target cancerous cells in an in vitro setting. 
4.2 Materials and Methods 
4.2.1 Materials 
In addition to materials introduced in section 3.2.1, holo-Transferrin, Traut’s reagent, and choles-
terol were from Sigma-Aldrich (St. Louis, USA).  Distearoyl phosphatidylethanolamine–PEG 
[2000 d] was purchased from Shearwater Polymers (Huntsville, AL).  HUVECs derived from sin-
gle donors were purchased from BD Biosciences (San Jose, CA).  Medium 200 phenol red free 
(PRF), low serum growth supplement (LSGS), trypsin/EDTA, and trypsin neutralizer solution were 
all purchased from Life Technologies Corporation (Carlsbad, CA).   
4.2.2 Cell culture maintenance 
K562 Cell Culture: This culture was described in section 3.2.2. 
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HUVECs Culture: HUVECs were plated in T75 flasks and fed with fresh medium every 36 hours.  
When confluent, cells were detached with 0.025% trypsin and 0.01% EDTA in PBS, neutralized 
with trypsin neutralizer solution (phosphate-buffered saline (PBS) containing calf serum), centri-
fuged at 125 ×g for 5 minutes, and re-suspended in the growth medium.  
All cultures were routinely monitored under an EvosTM AME-i2111 Digital Inverted Microscope, 
and when necessary, phase contrast micrographs were obtained at random locations. 
4.2.3 Synthesis siRNA containing liposomal particles [122], [123] 
A mixture of 260 nmol of distearoyl phosphatidylethanolamine–PEG [2000 d] and 3877 nmol of 
cholesterol was added to 5 mL of chloroform.  The lipid film was formed by allowing the solvent 
to evaporate overnight.  Then, 5 mL of MES buffer was added and stored in the dark for 2 hours.  
Liposomes were formed by strong vortex, 15 seconds of heating at 38 ᵒC in a water bath, followed 
by strong vortex.  At this stage, the samples were split into two groups: the first group was used, 
then stored for further testing, and the second group was used in holo-transferrin conjugation.  
Holo-transferrin conjugation:  A mixture of 260 nmol of holo-transferrin, and 10390 nmol of 
Traut’s reagent was prepared in 2 mL of EDTA buffer (pH: 8.5).  The mixture was shaken in the 
dark for 1 hour.  The solution was re-concentrated to 0.2 mL using Amicon® Ultra-2 filters (3 kDa, 
Sigma Aldrich) by centrifugation for 12 mins 3500 rpm at room temperature.  The concentrated 
solution was added in a 1:1 ratio to the freshly prepared micelles, as described above.  The mixture 
was stirred in the dark for 24 hours.  The samples were divided into two groups: the first group was 
stored for further testing, and the second group was used for siRNA. 
siRNA encapsulation: A 2.5 µM stock solution of siRNA was prepared in citrate buffer (pH 6.0 – 
Sigma Aldrich).  The lipid was dissolved in 100% ethanol, heated at 60 ᵒC, and added to siRNA 
solution (36 nM final concentration) under strong vortex.  Micelles were formed as stated above.  
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Sizing and purification:  The prepared liposomes solution was extruded through an extrusion device 
(T&T scientific corporation, Knoxville, TN, USA) with a 100-nm diameter filter, 21 times, follow-
ing the vendor’s instructions.  Dialysis was then performed in HBSS through MWCO 6000-8000 
(Cellu Sep T2, Membrane Filtration Products, Inc., Seguin, TX, USA) for 3 hours at room temper-
ature to remove the ethanol and raise the external pH.  Sepharose CL-4B ((Sigma Aldrich, St. Louis, 
MO) was packed into columns (Sigma Aldrich, St. Louis, MO), allowed to settle overnight at 4 C 
and used to remove unconjugated transferrin and other impurities. 
Dynamic light scattering (DLS) was performed using a zeta potential analyzer (Brookhaven Instru-
ments Corporation, NY, USA).  Using the associated software, the effective diameter of the parti-
cles population and its polydispersity were determined.  The zeta potential was also determined 
using the same apparatus.  
Transmission electron microscopy (TEM) was performed using JEOL JEM-2100 with Evex EDS 
(Peabody, MA) to visualize the liposomal particles.  Samples were stained with phosphotungstic 
acid, then placed on a TEM grid and imaged immediately.  The images show that the particles are 
spherical in shape and are less than 100 nm in size.  
4.2.4 Loading efficiency of siRNA in liposomes 
Liposomes were encapsulated with Alexa-Flour 488-conjugated BCR-ABL siRNA (F-siRNA, In-
tegrated DNA Technologies) to detect encapsulation efficiency and uptake by cells.  Since both 
free F-siRNA and encapsulated F-siRNA contributes to the fluorescence intensity, samples were 
collected before and after purification via Sepharose CL-4B packed column.  Fluorescence inten-
sities were measured using a Gemini XPS spectrofluorometer (Molecular Devices, CA) at an exci-
tation wavelength of 488nm and an emission wavelength of 530 nm.  Liposomes with siRNA were 
used as blank controls.  A calibration curve was prepared using 0 – 0.25 µM concentration of free 
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F-siRNA to convert, fluorescent intensities into concentration.  Loading efficiency was determined 
by taking the ratio of the two concentrations.   
4.2.5 Holo-transferrin conjugation efficiency 
Holo-transferrin-conjugated liposomes were purified using a Sepharose CL-4B packed column to 
remove any unconjugated particles.  The amount of holo-transferrin conjugated to liposomes was 
determined using BCA assay (Thermo Fisher Scientific, Waltham, MA), according to the vendor’s 
protocol.  In brief, absorbance was measured using Spectramax Emax (Molecular Devices, CA) at 
595 nm in a 96 well plate.  Based on a calibration curve prepared using standard solutions (125 – 
2000 µg/mL), the total amount of protein in the sample was quantified.  Using the total amount of 
holo-transferrin added during preparation, the conjugation efficiency was calculated.  
4.2.6 Determination of BCR-ABL downregulation using quantitative polymerase chain re-
action (q –PCR) 
Free siRNA (36 nM) was incubated with 2×105 K562 cells/mL for 72 hours.  The samples were 
snap frozen at -80 o C.  An RNeasy mini kit was used to purify RNA samples and RNA concentration 
in each sample was measured using NanoDrop Spectrophotometer (ND-1000).  The complemen-
tary DNA (cDNA) kit, iScript Reverse Transcription Supermix for RT-qPCR (BIO-RAD), was 
used to obtain cDNA for the collected RNA samples.  Mastercycler (Eppendorf) was used to run 
the reverse transcription process.  β-glucuronidase (GUSB) was used as the standard gene, as sug-
gested for K562 cells [124].  Primers for the GUSB were designed using Primer-BLAST while the 
primers for the BCR-ABL gene were purchased (ThermoFisher Scientific,) based on literature re-
ports [125].  SYBR Green Supermix (BIO-RAD) was added to all samples.  qPCR was performed 
by CFX Connect Real-Time System (BIO-RAD), and the results were analyzed using Bio-Rad 
CFX Manager 3.0, and MS Excel.  The expression fold change (EFC) method was used to quantify 
BCR-ABL downregulation in K562 cells. 
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4.2.7 siRNA-loaded liposomes effect on cell viability 
For all experiments, K562 cells were harvested, counted using a Hemocytometer, and 2×105 
cells/mL were cultured in a 6-well plate with 2 mL of fresh media for each well.  siRNA concen-
tration was 36 nM in all the samples as follows: i) controls prepared by directly adding citrate buffer 
solution equivalent to that present in 36 nM siRNA solution, ii) free siRNA, iii) scrambled siRNA, 
iv) PEG-Liposomes with no siRNA, v) siRNA- loaded PEG-liposomes, and vi) siRNA-loaded-
holo-transferrin conjugated PEG-liposomes.  All cell cultures were incubated for 72 hours, K562 
cells were collected by centrifugation at 840 ×g for 5 minutes, and viability was determined using 
the method previously reported [73].  In brief, cells were washed with phosphate buffer solution 
(PBS, 7.2 pH, prepared in-house using 8 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, and 2.17 g Na2HPO4-
7H2O in 975 mL DI water) with 0.1% BSA (1 mL for every 2×10
5 cells).  Then cells were washed 
with Annexin V buffer solution and stained with 2 µL Annexin V FITC conjugate, then with 4 µL 
of PI (100 mg/L), and then incubated in ice for another 15 minutes. Samples were analyzed using 
a FACSCalibur (Becton Dickinson, San Jose, CA) flow cytometer.  Unstained samples and indi-
vidually stained samples were used as controls.  Based on the obtained information, the percentages 
of dead cells were determined using a standard quadrant analysis.   
4.2.8 Cellular uptake of siRNA and siRNA-loaded liposomes 
Free F-siRNA, F-siRNA-loaded and unloaded holo-transferrin-PEG-liposomes were prepared.  
The samples were incubated for 5 days i) without any cells, ii) with K562 cells, and iii) with K562 
cells and HUVECs.  HUVECs were seeded on 6-well plates in preparation for experiments.  The 
other cell line and treatment elements were then added.  Cell medium was prepared in 1:1 (by 
volume) of RPMI: 200 medium.  Micrographs were collected for all conditions after 0, 24, 72, and 
120 hours using an Evos digital microscope.  Non-adherent K562 cells were gently collected by 
withdrawing 100 µL cell medium each day and analyzed by flow cytometry for the presence of F-
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siRNA.  On the fifth day, all K562 cells were removed by gentle mixing and then HUVECs were 
detached using trypsin/EDTA and analyzed for the presence of F-siRNA.  In order to minimize the 
presence of both cell types, forward scatter and side scatter data were used as both cells have dif-
ferent sizes and granularity. Three biological samples were prepared for each condition.   
4.2.9 Influence of resveratrol on HUVECs   
In order to assess the effect of released resveratrol, changes in Sphingosine 1-phosphate (S1P) was 
measured using ELISA kit (MyBioSource Inc., CA) following the vendor’s protocol.  Following 
conditions were prepared in 1:1 RPMI:200 PRF cell medium: i) 2×105 cells/mL K562 cells without 
resveratrol; ii) 2×105 cells/mL K562 cells with 40 µM of resveratrol; and iii) Both K562 cells and 
HUVECs (2×105 cells/mL) where HUVECs were seeded first, allowed to attach, and then K562 
cells were added along with 40 µM of resveratrol.  Cell culture medium without any cells was also 
cultured in tandem with cell cultures.  Samples (50 µL) were collected at 0, 24, 48, and 72 hours, 
and stored at -20 ᵒC for further analyses.  Absorbance was measured using Spectramax Emax (Mo-
lecular Devices, CA) at 450 nm in a 96 well plate.  Based on a calibration curve prepared using 
standard solutions (0 – 200 ng/mL), the S1P content in the sample was quantified.  S1P activity in 
the culture medium without cells was used as blank for respective time points.  
4.2.10 Resveratrol and siRNA combination effect on K562 cell viability 
Effect of resveratrol encapsulated microfibers in combination with siRNA-loaded liposomes on 
K562 cell viability was evaluated over 8 days.  For all conditions, K 562 cells at 2×105 cells/mL 
were used with PRF cell culture medium.  The following conditions were prepared:  i) 36 nM 
siRNA and 40 M resveratrol both introduced directly to the cell culture medium; ii) Controls 
prepared by adding fresh medium only; iii) Fibers (with no resveratrol) introduced into cell medium 
on day 0; iv) Fibers with 40 M resveratrol and liposomes with 36 nM siRNA both introduced at 
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the same time on day 0; v) Fibers with 40 M resveratrol introduced on day 0, and liposomes with 
36 nM siRNA introduced on day 3 referred to as delayed liposomes + microfibers.  Micrographs 
were taken at random locations after 0, 72, 120, and 192 hours for each sample. On days 3, 5 and 
8, cultures were mixed gently and 50L samples were collected.  These samples were analyzed for 
K562 cell viability using two-color flow cytometry.   
4.2.11 Resveratrol and siRNA combination effect on K562 cell viability in the presence of 
HUVECs 
In order to understand the combination effect in presence of HUVECs, co-culture experiments were 
performed.  HUVECs were seeded first, allowed to attach, then fibers were introduced followed by 
the addition of K562 cells.  All samples were incubated in 1:1 ratio of RPMI (with 10% FBS) and 
200 PRF medium.  The following groups were used: i) controls prepared by adding fresh medium 
only; ii) Fibers with 40 M resveratrol and liposomes with 36 nM siRNA both introduced at the 
same time on day 0; iii) Fibers with 40 M resveratrol introduced on day 0, and liposomes with 36 
nM siRNA introduced on day 3 referred as delayed liposomes + microfibers.  Micrographs were 
taken at random locations after 0, 72, 120, and 192 hours for each sample. On days 3, 5 and 8, 
cultures were mixed gently and 50L samples were collected.  These samples were analyzed for 
K562 cell viability using two-color flow cytometry. 
4.3 Results 
4.3.1 Liposomes characterization 
Liposomes were prepared in-house as described in the previous section.  Hence, I first characterized 
the particle size and efficiency of holo-transferrin conjugation.  Then samples were visualized in 
TEM, which (Figure 4.1a) showed that the particles were around 100 nm in diameter and the par-
ticles were spherical with well-defined edges.  DLS analysis of five replicates showed that the 
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effective diameter of the particles was 117.2 (±1.53) nm, with a polydispersity of 0.170.  Zeta 
potential outcome of ten replicates was -11.09 (±0.82) mV.  The latter was found to be similar to 
values reported in the literature [126].  
In order to understand the total transferrin present, BCA assay was performed.  These results (Fig-
ure 4.1b) showed the concentration to be 3300 (± 334) µg/mL in holo-transferrin containing lipo-
somes and the amount of protein in unconjugated liposome was 1.8 (± 0.17) µg/mL.  Then I calcu-
lated the efficiency of loading using the total amount of holo-transferrin initial added (3850 µg/mL) 
during the conjugation.  Calculated conjugation efficiency was 85.9 (±7.30)%.  The total amount 
of siRNA added during the synthesis procedure was 0.72 µM.  After purification of liposomes, the 
measured siRNA concentration was 0.66 µM.  This resulted in the loading efficiency of siRNA in 
the liposomal particles to be 92.3 (± 2.57) %.  
 
 
Figure 4.1: Liposomes characterization. (a) TEM image showing spherical liposomes. 
(b). Comparison of total protein content in holo-transferrin-conjugated liposomes with un-

































4.3.2 Silencing BCR-ABL in K562 
In order to understand the effect of RNA interference to silence BCR-ABL gene expression in K562 
cells, the RT-qPCR analysis was performed after 72 hr of exposure.  The results show (Figure 
4.2a) significant knockdown of the BCR-ABL mRNA in the sample treated with 36 nM BCR-ABL 
siRNA with respect to a control (untreated sample), and in addition to scrambled RNA.  Compared 
to the control sample, there is roughly a 60% decrease in the expression of the BCR-ABL gene.  
Liposomes loaded with siRNA samples gave similar silencing effect compared to free siRNA.  This 
is attributed to single culture effect, where the treatment is solely introduced to K562 cells.  The 
cellular non-viability level achieved with the same concentration of siRNA was 46.3 (± 2.97)% 
[73].  In contrast, scrambled siRNA showed around 20% decrease in the expression of BCR-ABL.  
This correlated to the K562 cells non-viability rate of 15% [73], observed after 72 hours of incuba-
tion with a scrambled siRNA as a positive control.  With increased siRNA dosage, it is expected 
that the knockout would proportionally increase [73].  Since I wanted to use 36 nM concentration 
in subsequent combination experiments, I did not perform dosage effects on the knockdown.  
4.3.3 Effect of siRNA-loaded liposomes on cell viability. 
In order to assess the effectiveness of loaded siRNA into holo-transferrin conjugated PEG-lipo-
somes, cell non-viability was measured using two-color flow cytometry.  The K562 cell non-via-
bility level induced by siRNA containing holo-transferrin conjugated PEG-liposomes (Figure 
4.2b), and PEG-liposomes, was slightly higher than those unconjugated.  Compared to free-siRNA, 
these results show that BCR-ABL siRNA activity was not altered, suggesting the process of loading 
and formation of liposomes does not affect siRNA activity.  These levels were similar to the apop-
tosis levels achieved with free siRNA, however, the necrosis level is significantly reduced.  Both 
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scrambled and unloaded liposomes (used as positive controls) showed significantly lower non-vi-
ability levels than siRNA treated samples.  This effect of inducing higher levels of apoptosis com-
pared to necrosis is desirable. 
 
4.3.4 Uptake of liposomes by K562 cells. 
The uptake of siRNA by K562 cells was observed using fluorescent siRNA.  The control samples 
prepared with empty liposomes showed (Figure 4.3) a very low percentage of uptake; these could 
be attributed to the background signal.  Free siRNA samples showed an uptake rate significantly 
higher than control samples, and it peaks after 4 days of incubation.  Samples, where siRNA was 
loaded into holo-transferrin conjugated PEG-liposomes, showed that after 1 day of incubation, the 
uptake percentage in K562 cells was not significantly different than that achieved with free siRNA. 
 
Figure 4.2: Effect of siRNA on K562 cells.  (a) Real-time q-PCR analysis using expression 
fold change.  Results show the relative fold change of BCR-ABL expression. (b) K562 cells 
non-viability analysis after 3 days of incubation.  Indicated non-viable cells were assessed by 
two-color flow cytometry was used to analyze apoptosis with Annexin V and necrosis with PI. 
Medium sample refers to free siRNA in k562 cell medium.  Lip + siRNA refers to holo-
transferrin conjuagated PEG-liposomes loaded with siRNA.  PEG-Lip and PEG-Lip + siRNA 
refer to unconjugated liposomes without and with siRNA loading, respectively. The asterisk (*) 









































































However, the uptake percentage significantly differed between the two groups after 2 days of in-
cubation.  With siRNA-loaded liposomes, the uptake peaks after 4 days of incubation.   
In order to test the effectiveness of prepared liposomes in targeting, I evaluated the uptake of siRNA 
by K562 cells in the presence of non-cancerous adherent HUVECs in co-culture.  Hence, both cell 
types were individually harvested without the need for cell sorting.  The same increasing trend was 
observed in the uptake of siRNA by K562 cells similar to the condition without HUVECs, with a 
minor reduction.  Uptake peaked at 4 days of incubation.  I also analyzed siRNA content in HU-
VECs by collecting after trypsin/EDTA treatment after 5 days.  On average, 23.6 (± 1.38) % of the 
HUVECs had siRNA.  In comparison, 73.1 (± 1.18) % of K562 cells had siRNA on day 5.  When 
these co-cultures were observed under a microscope (Figure 4.4), K562 cells clustered around the 
adherent HUVECs, unlike monocultures where K562 cells were uniformly distributed.  This could 
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Figure 4.3:  K562 cells uptake level of Alexa-Flour 488 conjugated siRNA (F-siRNA). Flow 
cytometry results of liposomes with no siRNA used as control samples, Free siRNA refers to 
F-siRNA in cell medium, Liposomes + siRNA refers to F-siRNA loaded-liposomes, and Lipo-
somes + siRNA + HUVEC refers to F-siRNA loaded liposomes in the presence of HUVECs. 
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interfere in nutrient distribution and/or liposomes to HUVECs.  Based on this experiment and pre-
vious findings [73], nearly all siRNA that cells uptake induces cell death.  This is interpreted by 
comparing the free siRNA uptake after 3 days, to the non-viability induced by free siRNA under 
the same conditions.  The former shows 49.03 (± 0.92) %, compared to the latter which shows 
46.32 (± 2.97) %.   
4.3.5  Stability of liposomes in cell medium.   
To test liposomes stability in cell medium, they were first loaded with fluorescent siRNA (F-
siRNA).  The prepared samples were incubated in cell medium under the same conditions used in 
all experiments, to ensure stability of liposomes under these conditions.  Stable liposomal particles 
produce a fluorescent signal, due to loaded F-siRNA, that corresponds to their size, which is sig-
nificantly larger than that of free siRNA molecules.  Results show that over 5 days period, roughly 
85% are intact and stable (Figure 4.3).  The remaining percentage is attributed to undesirable re-
lease, or unsuccessful loading of F-siRNA.  That percentage could also be due to dissociation of 




Figure 4.4: Microscopic images of K562 cells in the presence of HUVECs. The control sam-




4.3.6 Effect of bolus doses of resveratrol on HUVECs. 
Previously, I showed the fate of resveratrol during the 3-day cell culture in K562 cell culture me-
dium which contains 10% FBS.  The linear fit equation to the obtained data gave a value of 70.4 
hours, confirming complete depletion at 72 hr.  Experiments performed in the absence of cells 
showed an exponential decay and a half-life (t1/2) of 89.6 hours, nearly three times longer than that 
reported in the plasma [92].  In co-cultures, I used 1:1 HUVECs medium and K562 cells.  The 
absence of FBS in HUVECs culture medium reduces the total FBS content.  Resveratrol uptake by 
cells is thought to be mediated via binding to lipoproteins and albumin [108].   
Next, I tested the effect of 40 µM resveratrol alone on HUVECs viability after 3 days of exposure.  
Resveratrol-induced HUVECs death (Figure 4.5a) was not significantly different than the control 
cultures with no resveratrol.  This is similar to that reported in the literature, although their analysis 
was after 24 hr and with half the resveratrol concentration [127].  Also, the presence of K562 cells 
did not affect the viability significantly.  This suggests that the resveratrol at 40 µM dosage is not 
harmful to HUVECs.   
Resveratrol inhibits the sphingosine kinase 1, which affects the production of S1P [128].  Level of 
S1P reduced in K562 cells treated with resveratrol (Figure 4.5b) in relation to untreated K562 cell 
cultures.  K562 cells are hyperactive and are associated with a high uptake rate of resveratrol.  A 
similar influence is noted in the literature [128], while different concentrations of S1P are obtained 
due to a different cell density used in each case.  In any case, the S1P level seems to increase in 
presence of HUVECs, particularly at day 3.  Many have shown the protective effect of resveratrol 




4.3.7 The release of resveratrol from microfibers.  
The release of resveratrol from different microfibers configurations, in single cell culture, as shown 
in Figure 3.5b.  The presence of both polymers and resveratrol have been confirmed by FTIR [130] 
and differential scanning calorimetry [131].  To understand the uptake and release kinetics of 
resveratrol from microfibers, its content in the medium was analyzed using HPLC analysis [73].  
The release of resveratrol from fibers without cells reached 100% by 72 hours of incubation from 
single fibers (Figure 4.6).  Similar trends were observed in the presence of K562 cells as well as 
HUVECs.  The highest concentration achieved was lower than the medium alone cultures.  I did 
not account for the decay or the uptake of resveratrol by cells during the incubation time.  Hence, 
those differences could be attributed to the uptake by cells similar to bolus experiments.  Also, 
initial release rates in HUVECs were higher, suggesting those differences are related to the uptake 
rate by cells.   
 
Figure 4.5:  Influence of resveratrol on HUVECs viability/activity. (a) Influence of resvera-
trol on HUVECs viability after 72 hours.  Control refers to untreated cells in cell medium, Co-
Control refers to untreated cells in 50:50 cell medium.  Indicated non-viable cells were assessed 
by two-color flow cytometry using Annexin V for apoptosis and PI for necrosis.  (b) Effect of 
resveratrol on Sphingosine-1-phosphate levels.  Values obtained from 1:1 culture medium was 
used as blank. Asterisk (*) indicates P < 0.02 relative to 0 (hr) sample, # indicates P < 0.02 





4.3.8 Effect of combination therapy using microfibers and liposomes on cell viability. 
Since our intent was to understand the effect of combination of siRNA and resveratrol control de-
livery devices on non-viability of K562 cells, first, I performed experiments using single fibers 
loaded with 40 M resveratrol and liposomes loaded with 36 nM siRNA in two treatment modes i) 
fibers and liposomes added simultaneously and ii) liposomes added three days later than fibers.  
This delay was based on the release kinetics of resveratrol from fibers in achieving drug level, 
similar to the bolus doses.  A gradual increase in apoptotic cells was observed when both drug 
delivery devices were introduced simultaneously (Figure 4.7a).  At day 8, simultaneous addition 
had 86 (± 3.8) % non-viability level, which was significantly higher than the control samples pre-
pared in PRF medium only.  I did not change medium during 8-day cultures to avoid disturbance 
introduced to the concentration of drugs and observed cell death in controls could be due to nutrient 
limitation.   
 
Figure 4.6: Resveratrol release and activity. Release study of resveratrol from electrospun 
fibers in the presence and absence of HUVECs.  Control refers to unloaded electrospun single 
fibers.   
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In cultures where liposomes were delayed by 3 days, non-viability was lower at day 3 but signifi-
cantly increased on day 5 and reached 92.7 (± 1.63) % after 8 days of incubation.  Reduction at day 
3 is expected as there is no liposome.  Over an extended time scale, however, delayed liposomes 
introduction resulted in higher total non-viability.  Also, bolus doses of 40 M resveratrol and 
liposomes loaded with 36 nM gave 78 (± 2.3)% at day 3 [73].  This suggests the possibility of 
achieving therapeutic levels locally, long-term, and more effectively.  I also assessed the necrotic 
cells using the PI (Figure 4.7b).  In relation to non-viable cells, necrotic cells were significantly 
lower in treated groups, similar to the control group.  This also suggests that the control samples 
show such levels probably due to reduced nutrition level.  
 
Next, I compared the micrographs at various time points during the culture time (Figure 4.8).  As 
expected in the control group, the number of K562 cells increased progressively.  Compared to 
control samples, K562 growth in treated samples seemed to be reduced or appeared similar to the 
 
Figure 4.7: K562 cells non-viability levels investigated under different conditions.  Indi-
cated non-viable cells were assessed by two-color flow cytometry using Annexin V for apop-
tosis and PI for necrosis.  Free samples correspond to free resveratrol in cell medium. Control 
samples correspond to K562 cells and cell medium without treatment. Fiber samples are single 
fibers loaded with resveratrol and introduced to cell medium. Lip + fiber correspond to samples 
treated with both loaded liposomes and loaded fibers, introduced to cell medium simultane-
ously. Delayed Lip + Fib samples correspond to loaded fibers introduced to cell medium im-
mediately, and loaded liposomes introduced to cell medium after 72 hours.  Part (a) shows 
Annexin V stained samples (non-viable cells), part (b) shows PI stained samples (necrotic 




day zero samples.  Also, cells were distributed around the fibers.  In addition, the structure of mi-
crofibers seemed unaltered by the presence of neither K562 cells nor siRNA-encapsulated lipo-
somes. 
4.3.9 Resveratrol and siRNA combination effect on cell viability in the presence of HUVECs 
In order to understand the effect of targeted combination therapy on K562 cells, I first seeded HU-
VECs and performed experiments similar to Section 3.7.  A primary difference was the cell culture 
medium which was 1:1 mixture of HUECs culture medium and K562 cell culture medium.  These 
results showed non-viability of K562 cells (Figure 4.9a) is not higher than that observed in mono-
culture results (Figure 4.7a) for both treatment options; non-viability levels of K562 cells were 
79.99 (± 2.24) % and 94.32 (± 1.70) %.  This indicates that the treatment by inducing apoptosis in 
K562 cells is not affected by the presence of HUVECs and that the treatment is still effective.  There 
 
Figure 4.8: Microscopic images of the combination therapy on K562 cells. Controls corre-
spond to monocultures in 200 PRF medium.  
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also seemed to be an increase in non-viability with delayed addition of liposomes, particularly be-
tween day 3 and day 5.  However, the control group showed a higher percentage of non-viable cells 
on day 8.  When necrotic cells were analyzed (Figure 4.9b), there was a higher percentage of 
necrotic cells in all groups relative to monocultures (Figure 4.7b).  This could be due to an en-
hanced effect of nutrient deficiency, with increased cell number and no replenishment of culture 
medium during 8-day cultures to avoid issues with drug concentration.  
On the eighth day, I harvested HUVECs and tested viability (Figure 4.9c).  These results showed 
48.0 (± 4.35) % non-viable cells, and 40.9 (± 4.79) % necrotic cells in treatment groups and com-
parable numbers in control.  The increase in non-viability levels in controls could be due to lack of 
nutrition over 8 days of incubation in 1:1 RPMI: PRF 200 cell medium. 
 
Micrographs captured during incubation showed the presence of adherent HUVECs in the bottom 

























































































(a) (b) (c) 
Figure 4.9: K562 cells non-viability levels investigated under different conditions. Indi-
cated non-viable cells were assessed by two-color flow cytometry using Annexin V for apopto-
sis and PI for necrosis.  Control samples correspond to K562 cells and HUVECs in 1:1 RPMI 
and 200 medium without treatment.  Lip + fiber correspond to samples treated with both loaded 
liposomes and loaded fibers, introduced to the co-culture cell medium simultaneously.  Delayed 
Lip + Fib samples correspond to loaded fibers introduced to the co-culture cell medium imme-
diately, and loaded liposomes introduced to the co-culture cell medium after 72 hours. Parts a, 
and b correspond to non-viable, and necrotic, respectively. Parts c is non-viability analysis for 
the corresponding samples after 8 days.  Part (a) shows Annexin V stained samples (non-viable 
cells), part (b) shows PI stained samples (necrotic cells).  Part (c) shows the same analysis on 
HUVECs after 8 days of incubation.   Asterisk (*) indicates P < 0.02 relative to control samples.  
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in the control samples is viable.  On day 3, HUVECs were still intact, yet slowly lost their adhesive 
feature by day 8.  K562 cell growth was also limited in co-culture.  In any case, the stability of 
fibers was not altered by the presence of HUVECs.  
 
4.4 Discussion 
Available treatment options including chemotherapeutic drugs have significant side effects apart 
from poor solubility in an aqueous environment, short circulating times, and nonspecific delivery.  
Higher dosages used to achieve therapeutic levels of promulgating toxicity.  In order to mitigate 
these issues, various controlled delivery devices with targeting have been intensely investigated 
[96].  For example, doxorubicin encapsulated in liposomes (e.g. DOXIL®) provides a therapeutic 
effect [128].  These biocompatible liposomes with very low toxicity show significant potential in 
many delivery systems, with high in vivo response [132].  PEG coating (to overcome rapid clear-
 
Figure 4.10: Micrographs of the combination therapy on K562 cells in presence of HU-
VECs.  Controls correspond to co-cultures in 1:1 RPMI and 200 PRF medium. 
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ance from circulation) and ligand attachment (to avoid non-specific binding) are important for tar-
geting [42].  Transferrin-receptors, overexpressed in cancer cells, including K562 cells, provide 
higher binding efficiency and multiple fold decrease in IC50 value compared to non-targeted lipo-
somes [42].  However, there has been significant side effects (e.g. hand-foot syndrome) due to 
premature leakage and high dosage requirement.  Forming core-shell nanoparticles have been ex-
plored to minimize premature leakage [113].  Combination treatment has been explored with mul-
tiple drugs encapsulated into liposomes, or multilayered nanoparticles [62, 63].  
In this chapter, I evaluated the possibility of combining two separate delivery methods to deliver 
two different drugs.  Aside from the advantages provided by the combination of two drugs, the 
separate delivery systems provide flexibility and better control upon release.  First, I used siRNA 
targeting BCR-ABL delivered through holo-transferrin conjugated PEG-liposome.  Second, I pre-
pared electrospun fiber for controlled release of resveratrol [98], which is proposed in cancer ther-
apy [82, 83].  In Chapter III, I showed that delivering lipophilic resveratrol and achieving thera-
peutic levels in cell culture in five days [73].  This is a significant improvement, as clinical trials 
with 150 mg/day of resveratrol given to healthy volunteers for 30 days showed plasma levels in the 
nanomolar range [91].  This is nearly three orders of magnitude less than that required micromolar 
concentration to cause apoptosis in cancer cells in vitro.  Here, I showed that resveratrol-siRNA 
combination is more potent over 8 days using non-adherent K562 cells and in the presence of HU-
VECs [87].  Others have shown complete non-viability level, using 2 µM BCR-ABL siRNA trans-
ferrin conjugated PEG-liposomes [122].  I used 36 nM BCR-ABL siRNA, in the combination de-
livery system, showing that 92.7 (± 1.63)% non-viability level is achievable. 
Liposomal delivery of siRNA is via endocytosis, for which 100 nm diameter nanoparticles are 
optimal to avoid uptake by the reticuloendothelial system [133].  Others have shown that BCR-
ABL siRNA causes up to 84% of protein level suppression [10].  However, to the best of our 
knowledge, the level of apoptosis has not been reported.  Treatment with siRNA results in nearly 
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60% BCR-ABL gene silencing, and around 46% cell non-viability.  I also observed slightly higher 
uptake with holo-transferrin conjugated liposomes than unconjugated liposomes.  Others have 
shown similar silencing levels achieved with free BCR-ABL siRNA [122].  This indicates that the 
delivery system does not alter BCR-ABL siRNA activity.  Observed non-viability level might be 
due to treating a population of K562 cells in vitro with no exposure of other cells that can contribute 
to selectivity.  The uptake study suggests that free siRNA uptake by K562 cells is achievable, how-
ever, it is not as high as that achieved with liposomes encapsulation.  The uptake level of liposomes 
by K562 is slightly altered in the presence of HUVECs.  HUVECs contribute to the uptake of the 
total liposomes population, however, this uptake level is relatively low.  This suggests that cancer-
ous cells uptake of the surface modified liposomes is not significantly altered by the presence of 
healthy cells.  Since K562 uptake is significantly higher than that of healthy cells, the delivery 
method is highly selective.  This is attributed to the holo-transferrin conjugation, which binds to 
the holo-transferrin receptor, highly expressed in K562 cells. 
By independently loading the two molecules of different sizes and different characteristics, one can 
optimize the release rates and timing of administration independently.  I investigated two-time 
schemes.  The second (delayed liposomes introduction) time scheme induces higher non-viability 
level.  This can be attributed to uptake, and release profiles, respectively.  Our approach overcomes 
the limitations imposed by using one delivery vehicle for the release of multiple components [134].  
When introduced at the same time, both siRNA and resveratrol induce their effect on two different 
cellular pathways in K562 cells, simultaneously.  However, a higher effect is achieved if the lipo-
somes introduction into the system is delayed.  The latter scenario allows for the maximal effect of 
resveratrol to take place after being released in the first 3 days.  Liposomes uptake would then take 
place and exert its effect on K562 cells, resulting in higher non-viability levels.  One could admin-
ister these intravenously and locally.  The two-time schemes show how the two delivery methods 
can be controlled timewise to produce a maximal effect.  Timing the administration of the second 
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delivery device is also important.  Similar strategies can be easily adaptable in treating other cancer.  
Introducing the proposed electrospun delivery system can be applied to a broader range of cancer 
treatment as microfibers can also be used to deliver both lipophilic and hydrophilic molecules.  As 
K562 cells don’t attach, there is no hindrance to the resveratrol release from the fiber.  However, I 
do not know how cell adhesion to the fiber surface affects the release and effectiveness of the 
delivery device.  Further studies in understanding the effect of cell adhesion on release profile are 
needed.  In any case, I believe that similar combination therapy is applicable to existing cancer 
treatments to reduce dosage and side effects. 
In summary, BCR-ABL targeting siRNA was successfully loaded into holo-transferrin-conjugated 
liposomes of 110 nm in size.  Formed liposomes showed 3:1 specificity between cancerous K562 
cells in relation to healthy HUVECs in co-cultures.  A bolus dose of 40 µM resveratrol showed 
increased K562 cell death [73] but did not affect HUVEC cell death in relation to controls.  Serum 
added to the medium influences the stability of resveratrol in cultures.  Measured S1P activity 
showed reduced content due to inhibition of sphingosine kinase 1 in K562 cells.  Similar resveratrol 
release was observed from polycaprolactone-gelatin electrospun fibers in the presence of HUVECs. 
Combination of controlled release of resveratrol and targeted liposomes significantly affected K562 
cell apoptosis over 8 days.  Delayed addition of liposomes influenced these results further.  The 
effect of resveratrol and siRNA can be maximized with controlled administration.  The uptake 
study shows that K562 uptake of liposomes is not significantly altered by the presence of HUVECs.  
This indicates that similar uptake level is expected in vivo.  As a result of lower uptake level, non-
viability level of HUVECs is significantly lower than that in K562.  The combination therapy is as 
effective in the presence and absence of HUVECs.  These results are promising and need further in 
vivo investigation.  Alternatively, I developed a model in Chapter V which can be used to predict 
the effects of biological conditions on the delivery system.  This does not necessarily eliminate the 









Time-dependent increase in the level of non-viable cells was observed, correlating to the release 
profile.  However, it is not clear what approach is appropriate for administering the microfibers.  
One option for the treatment of leukemia is to insert locally at a site near the genesis of cancerous 
cells, i.e., bone marrow that hub for hematopoiesis.  Similar to a bone marrow biopsy procedure, 
or stem cell local administration [58], microfibers containing resveratrol can be placed within the 
bone marrow.  However, the influence of blood flow along with the uptake of resveratrol by cells 
is not well understood. 
With the advances in computational modeling, there has been an immense interest in screening 
therapeutic agents in silico with the intent of reducing the cost and time while improving the success 
rate of candidate drugs.  However, models that translate drug stability characteristics and transient 
release profiles to conditions used in 3D tissue mimicking that in vitro conditions needs to be de-
veloped.  Bioreactors provide a suitable in vitro 3D environment with controlled desired stimuli, to 
represent the bone marrow microenvironment [135].  This bioreactor configuration was assumed 
to mimic the bone marrow microenvironment [136].  They were used to estimate the average nu-
trition consumption in the bone marrow microenvironment.  
In this regard, I investigated the effect of introducing a fluid flow system, mimicking that of the 
blood perfusion, on the release of resveratrol from electrospun microfibers.  
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I used a combination of experimental results and computational fluid dynamics (CFD) to assess the 
effect of fluid flow rate, uptake rate by cells, length of the fibrous matrix, and the porosity of the 
tissue surrounding the blood vessels on the concentration profile of resveratrol.  I used the dimen-
sions based on a recent study done to understand the related kinetics of chemicals secretion by the 
bone marrow [137].  Two cell lines were included to understand the effect of uptake rates on re-
leased stimulants: 1) endothelial cells that line the blood vessel, and 2) K562 cells suspended in the 
fluid and based on empirical uptake rates.  Non-adherent K562 cells predominantly used in under-
standing the molecular mechanisms and treatment options. First, I validated the simulation ap-
proach using static and dynamic conditions.  Then I extended the simulation approach and show 
that porosity of the tissue and uptake rates have a significant influence on the concentration profile 
of resveratrol.   
5.2 Materials and Methods 
5.2.1 Stability of resveratrol in various cell medium 
To evaluate the stability of resveratrol in the culture medium, experiments were performed in 6-
well plates and 2 mL medium K562 cells and HUVECs.  Experiments were performed using 2×105 
cells/mL (total number of cells, 50% each cell line in the case of co-culture), and 40 µM concen-
tration of resveratrol in medium containing 1:1 of RPMI (used for K562 cells): 200 PRF (used for 
HUVEC culture) cell medium for 72 hours in 5% CO2, and 37 C, with and without cells.  Three 
conditions used were i) medium alone, ii) in presence of HUVECs, and iii) in the presence of both 
HUVECs and K562 cells.  Samples were collected every 24 hours from the initial time point and 
change in resveratrol concentration was assessed in samples using HPLC, as previously described 
[73].  Obtained concentrations were normalized to initial concentration and plotted as a function of 
time.  Data were fitted with an exponential equation to determine the cell uptake rates.  
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5.2.2 Diffusion coefficient calculations 
PCL-GT electrospun single fibers were formed identical to the procedure described previously.  
The experimentally determined concentration values were then used to calculate the corresponding 
total number of moles using the medium volume [73].  The dimensions of a 6-well plate were 
obtained from the product’s data sheet.  A single well has a diameter is 34.8×10-3 m, an area of 
9.51×10-4 m2, and a volume of 2 mL (amount of cell medium added in experiments).  The path of 
diffusion can be calculated by diving the volume over the area of a single well, resulting in 0.0021 
m.  The diffusion flux, 𝐽, was calculated for each individual point knowing the total moles.  Also, 
change in concentration, dC, during that time was calculated.  Knowing the thickness of the fiber, 
diffusion flux 𝐽 was plotted for the corresponding 
𝑑𝑐𝑖
𝑑𝑧
.  Then diffusion coefficient D was calculated 
using Fick’s first law as shown in Eq. 11.    
−𝐽 =  𝐷
𝑑𝐶
𝑑𝑧
        (11) 
From the slope of the linear function.  Obtained diffusivity values were used in the simulation.  
5.2.3 Measuring resveratrol release with fluid flow 
In order to understand the effect of fluid flow on the release profile of resveratrol, an apparatus was 
constructed in-house.  It consisted of a variable speed syringe pump (74900 series, Cole-Parmer, 
Vernon Hills, IL), syringe, a 12 cm long plastic (rigid) tube with an internal diameter of 0.6 cm, 
microfiber boundary condition, and a waste collector (Figure 5.1a).  A 3.8 cm long resveratrol 
containing PCL/GT fibers were inserted into a rigid tube, closer to the exit (Figure 5.1b).  The 
opposite end of the rigid of was attached to a 10-mL syringe containing cell culture medium, which 
was connected to the syringe pump.  The pump set to 0.001 mL/min (0.59 µm/s in simulation, 
calculated using the cross-sectional area of the reaction tube), used to pump RPMI (10% FBS) 
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medium though part 2 (Figure 5.1c).  Entire apparatus was incubated in 5% CO2/95% air, at 37 C.  
Samples (100 µL each) were taken at the exit using a 100 µL micropipette.  Eight samples were 
taken at 0, 10, and 50 minutes, followed by 5, 10, 24, 48, and 72 hours.  The samples were analyzed 
using HPLC as previously described [73].  The simulation parameters were modified to match the 
experimental dimensions. 
 
Figure 5.1: Experimental setup for model validation. (a) Experimental setup apparatus. (b) Top 
view of the reaction tube showing the location of the fiber insertion. (c) Illustration showing the 
dimensions and location of the fiber. 
5.2.4 Numerical simulation of resveratrol release from fibers.   
5.2.4.1 Geometry.  First, a 3D cylindrical tube was drawn with a 0.8 cm radius and 3.8 cm length 
(Figure 5.2a) in COMSOL Multiphysics 5.4.  These dimensions were based on a previous simula-
tion in the bone marrow microenvironment [137].  When evaluating the presence of surrounding 
porous tissue, an outer shell of 2.2 cm radius (Figure 5.2b) was added to the geometry.  In addition, 
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a 34-mm flat geometry was created using the dimensions of a 6-well plate, similar to prior experi-
mental setup for the release of resveratrol from electrospun fibers.  A coarse tetrahedral mesh was 
selected with the following element size parameters with a maximum element size of 0.00208 m 
and a minimum element size of 6.4×10-4 m.  Also, the maximum element growth rate was 1.25, the 
curvature factor was 0.8, and the resolution of narrow regions was 0.5.  Mesh independency test 
was performed, showing that the model is meshed independent. Physical properties (density and 
viscosity) of the cell culture medium were assumed to mimic that of water at 310.15 K (body tem-
perature).  Hence, two materials were defined, water, and resveratrol, defined by molecular weight 
and diffusion coefficient.   
 
Figure 5.2: Bioreactor model geometry. (a) A schematic showing the dimensions, flow inlet, 
outlet, diffusion, and the microfiber location. (b) A schematic including the surrounding porous 
media representing the spongy microenvironment of the bone marrow.  
 
5.2.4.2 Governing equations.  It was assumed that the entrance of the tube had a fully developed 
laminar flow to mimic blood flow in the bone marrow, and transport of diluted chemical, repre-
senting resveratrol, from the surface boundaries.  Multiphysics model was created to account for 
transport and laminar flow physics.  The two systems are correlated using flow coupling.  Fluid 
flow was assumed to follow incompressible Navier-Stokes equations given by Eq. 12, Eq. 13, and 






+ 𝜌(𝑢. ∇)𝑢 = ∇. [−𝑝𝑖𝑗 + 𝜇(∇𝑢 + (∇𝑢)
𝑇]    (12) 
  ∇. (𝑢) = 0        (13) 
  𝑢 =  −𝑈0𝑛          (14) 
where  is the density, p is the pressure,  is the dynamic viscosity, ij is the Kronecker delta 
function, u is the fluid velocity, U0 is the initial velocity, and n is the normal vector.  Initially, 
simulations were performed using 1.5 mm/s velocity [137].  However, while evaluating the effect 
of flow rate, these values were set to various flow rates as needed.  Also, for static condition, u was 
given a value of zero.  
In order to understand the effect of stability and uptake of resveratrol, unsteady advective- diffusion 
equation for the diluted chemical species was used.  This was represented in Eq. 15 and Eq. 16. 
𝜕𝐶
𝜕𝑡
+ ∇. (−𝐷∇𝐶) + 𝑢. ∇𝐶 =  𝑅      (15) 
𝑁 = −𝐷∇𝐶 + 𝑢𝐶       (16) 
where C is the concentration of resveratrol at any time t, D is the diffusion coefficient of resveratrol, 
R is the reaction rate, and 𝑁 is the molar flux.  The free diffusion coefficient was defined in the 
model as 1.84×10-7 m2/h.  The concentration profile was defined based on the release profile pre-
viously established [73].  The concentration profile, in the absence of cellular uptake, was defined 
from the fibers located at the boundary in Eq. 17.  
𝐶 = 5.74 + 33.45 (1 − 𝑒0.07𝑡)       (17)  
When evaluating the uptake rate and stability in the culture medium, reaction rate R was defined in 
the integral form using exponential equations from experiments.  For example, in the presence of 
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both HUVEC and K562 cells, the resveratrol uptake rates by cells as obtained from experiments 
(Eq. 18). 
𝐶𝑅 = 𝐶𝑅0 𝑒
−0.015 𝑡               (18) 
where CR0 is the initial resveratrol loading concentration, and t is given in hours.  When evaluating 
the transport of resveratrol to the surrounding porous region, the diffusion coefficient was modified 
to an effective diffusion coefficient (Deff) (Eq. 19).  The transport of diluted chemical species in 
porous media, Deff was assumed to remain constant, isotropic, and was approximated using Mackie-
Meares relationship [138].  





      (19) 
where p is the porosity value used in the simulation.  Based on the previously published reports a 
porosity of 8.6% was selected first and then to test the effect of porosity it was doubled.  
5.2.4.3 Boundary conditions.  No slip condition was assumed at the inner surface of the cylinder, 
where u = 0.  The Boundary condition for concentration release is defined at the surface, where 
material 2 (resveratrol) was defined at the inner surface only.  The global definitions of parameters 
and variables allow modeling for concentration release from the boundary.  The parametric values 
and model fit, as a function of time, were generated using previously established experimental re-
sults for a stagnant system [73].  These were solved using DIRECT solver system that is based on 
LU Factorization (12) to linearize and numerically solve the built-in PDE equations.   
5.3 Results 
5.3.1 Resveratrol stability as a function of medium and cellular uptake.   
When resveratrol is released into the bloodstream, it is exposed to luminal endothelial cells as well 
as cells suspended in the bloodstream.  In order to determine its fate, I performed co-culture exper-
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iments using HUVECs and K562 cells.  Also, a 1:1 mixture of the medium was used to accommo-
date the growth and survival of both the cells.  Then the fate of resveratrol in the culture medium 
of 1:1 RPMI:200 PRF medium, in the presence of K562 cells and HUVECs, was determined over 
a 3-day time period.  These results showed increased stability of resveratrol in culture medium with 
longer half-lives (Figure 5.3a).  Others have shown similar stability of resveratrol in phosphate 
buffers at similar pH conditions [139], [140].  However, I previously observed that in the presence 
of 10% serum, degradation is much faster.  Reduced serum level in the co-culture 1:1 RPMI:200 
PRF medium, reduces resveratrol degradation.   In the presence of HUVECs, the reduction was less 
compared to co-cultures, but higher than that in the medium.  Cancer cells are known to have altered 
metabolic activity [141].  In the presence of both HUVECs and K562 cells, nearly 38% remained 
in the cell culture medium at the end of 72 hours.  In addition, reduction in resveratrol seems to 
accelerate on day 3 in HUVECs, following a different trend line than the exponential decay ob-
served in K562 cell cultures.  
5.3.2 Resveratrol release profile matches with simulation results in stagnation condition.   
The release rate of resveratrol from the electrospun fibers was simulated using the 6-well geometry 
used in experiments over five days.  Five days were chosen based on available experimental results 
for the release of resveratrol using PCL-GT electrospun fibers in 6-well plates [73].  Similarly, flow 
through the reactor with zero velocity was simulated by representing simulation to occur as a 
boundary condition within the model, to generate a concentration profile (volume averaged) (Fig-
ure 5.3b).  In flat geometry, the concentration profile reached a plateau by 80 hr.  The experimen-
tally obtained concentration showed a similar release behavior, reaching a plateau by 72 hr but a 
faster release in the beginning.  The minor difference in the plateau value in simulations that ex-
perimentally obtained could be attributed to decay and variation in the loading of resveratrol.  Effect 
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of variation in the loading of resveratrol in fibers can be statically observed with the highest stand-
ard deviation obtained at the indicated time point, compared to all other experimental data points 
in the loading efficiency.  Slightly higher amount than that predicted can get loaded into the micro-
fibers used in the experiment (including the replicates). However, these do confirm that the simu-
lation approach is valid along with the underlying governing equations.  The effect of geometry 
was assessed using a cylindrical fibrous structure under fluid flow.  I used zero velocity, diffusion 
of diluted species is the only controlling phenomena dictating the observed final concentration pro-
file (Figure 5.3b).  Simulation results showed a faster release, in the beginning, relative to flat 
geometry.  Interestingly, no plateau region was observed.  I extended the simulation to 192 hr (8-
days) and no plateau region was observed.  Overall, the model successfully predicts the general 
concentration profile under stagnant conditions. 
 
Figure 5.3: Resveratrol stability and release under non-flow conditions. (a) Resveratrol degra-
dation analysis in 1:1 medium of HUVECs and K562 cells incubated at 37 C and 5% CO2. (b) 
Release profile simulation results in static conditions – no flow. 
 
5.3.3 Resveratrol release profile matches with simulation results in fluid flow condition.  
Experimental results were obtained using the tubular reactor set-up (Figure 5.1).  Nearly 8 cm near 
the inlet was purposefully introduced so that the fluid reaches a developed flow condition with 
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steady-state velocity profile that used in the simulations at the inlet condition.  These results (Fig-
ure 5.4) show that concentration profiles were identical between the experimental results and sim-
ulation results.  A minor difference was in the peak value reached by resveratrol, the simulation 
showed a lower peak relative to experimental results.  This could be attributed to a completely 
developed laminar flow inlet assumption in simulations, which might not have been perfectly 
achieved experimentally.  A flow pattern mimicking a plug flow could provide such increased con-
centration in tubular reactors.  Also, the presence of fibers and the surface roughness could alter 
the boundary layer leading to the variation in observed concentration profile.  Due to the higher 
standard deviation at the peak value could also be explained by the difference in the loading of 
resveratrol into the fiber during preparation.  In general, the model successfully predicted the actual 
concentration profile of resveratrol over five days, upon its release from microfibers.      
Time (hr)





















Figure 5.4: Experimental results validating the model under flow conditions. Blue model fit 
represents simulation results, compared to those experimentally generated (dark pink data points). 
The experiment and the simulation are performed under the same conditions: 37 ᵒC, no cellular 
uptake, geometry/dimensions, and cell medium properties. 
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5.3.4 Alteration in resveratrol concentration along the length of the reactor assuming flow 
conditions.   
After validating the simulation results with experimental results, I assessed the changes in the con-
centration of resveratrol along the length of the reactor.  For validation, the concentration profile 
over time was generated by taking an average value of the concentration over the entire volume of 
the reactor.  To determine the concentration distribution along with specific cross-sectional areas 
along the length of the reactor, the linear integration concept can be used and represented in the 
model using a linear projection operator [142].  To simplify this estimation, and reduce the com-
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     (20) 
Where z and r are the axial and radial directions in the study.  The concentration profile increases 
along the length of the reactor at a certain point in time (Figure 5.5a).  This is due to the flow effect 
starting at the inlet of the reactor and at the outlet.  Any amount of the chemical that is released at, 
or near the inlet, is carried towards the outlet.  The overall concentration distribution at the last 
point in time (120 hours) is shown in Figure 5.5b.  Table 5.1 shows selected time points where 










Table 5.1.  Alterations in the resveratrol concentration along the length of the tube at various 
time points. 
 
Figure 5.5: Cross-sectional area based concentration distribution by flow along the length of 
the bioreactor. (a) Linear integration release profile simulation at a selected point in time (120 h).  
(b) A 3D model of the concentration distribution. 
 
5.3.5 Influence of various parameter on the release of resveratrol under flow conditions.   
To understand the flow effects in fully developed (assumed at the entrance) laminar flow, the model 
was modified to include an inlet velocity.  Several variables were considered, including inlet ve-
locity, uptake rates of different cell types, and the length of the reactor.   

























0 µM  
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5.3.5.1 Impact of inlet velocity on the concentration profile.  The same model was used to predict 
the concentration profile over five days, varying three parameters: inlet velocity, cellular uptake, 
and reactor length (Figure 5.6).  Inlet velocity has a direct effect on the release kinetics.  The larger 
the velocity the faster a saturation condition is reached, and the faster resveratrol concentration 
starts to fall.  Changing the inlet velocity within the mm/s scale does not influence the concentration 
profile significantly, after 100 seconds.  Figure 5.6a shows that even 10 folds increase or decrease 
in the inlet velocity leads to the same general concentration profile.  Lowering the inlet velocity by 
an order of magnitude, however, had a significant effect on the shape of concentration profile over 
time.  As expected, the driving force reduces, leading to delayed maximum concentration level.  
The lower threshold is also encountered due to the wash away effect by inlet flow.  While it takes 
longer for the maximum concentration level to be reached, the flow effect is still washing away the 
diffused resveratrol, leading to a lower maximum level. 
The initial 2 hours of release varies based on the inlet velocity (Figure 5.6b).  This is expected due 
to having the maximum driving force initially.  As the initial concentration in the reactor is 0 µM, 
and the boundary concentration is at its maximum value, a concentration gradient is greatest, and 
therefore, mass transfer is greatest.  Once a threshold is reached, that value stabilizes, then starts to 
decrease due to flow condition.  The larger the inlet velocity the faster that threshold is reached.  
This is due to maintaining a high driving force.  As the velocity is higher, the diffused resveratrol 
is washed away quicker, leading to lower instantons concentration inside the reactor.  This driving 
force, however, leads to the higher release of resveratrol from the boundary per unit time.  The 
model, hereby, satisfies the general transfer phenomena predictions.  This shows that the process 
is convection dominant during the first few hours under the given perfusion rate. 
5.3.5.2 Impact of cellular uptake on concentration profile.  As the inlet velocity is fixed at 1.5 
mm/s, the effect of cellular uptake rates was evaluated using experimentally generated data.  the 
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simulation.  General behavior (Figure 5.6c) was similar to that in Figure 5.6a, except that addi-
tional cellular uptake reduced the available resveratrol concentration due to fluid flow.  Next, up-
take rates by different cell lines were included using the expression from experimental results.  
First, the presence of HUVECs, which line the blood vessels, were analyzed.  Due to the uptake by 
HUVECs, a lower release profile was observed, compared to no cellular presence.  The presence 
of additional K562 cells further decreased that profile.  This is expected due to the lower availability 
of the drug as the level of consumption increases.  This can be further developed to include enzy-
matic kinetics impact of the drug stability, among other biological factors.  For comparison pur-
poses an additional profile was generated using lower velocity (three orders of magnitude lower), 
compared to Figure 5.6a, the same general curve shape is obtained at a lower concentration at each 
point in time, due to the uptake rates introduced. 
5.3.5.3 Impact of reactor length on concentration profile.  To understand the effect of varying 
the bioreactor’s length, Figure 5.6d shows that increasing the length of the reactor by two, or ten 
folds does not have a noticeable overall effect on the concentration profile over the given period of 
time.  Also, different orders of magnitude in length were assessed.  Those scales, such as µm and 
m ranges produced a different release profile.  Those results, however, are unrealistic, as this model 
is supposed to represent an insertion section to the bone marrow which is realistically represented 
by the length studied in the model.  This shows that the process is diffusion dominant during the 
second part of the release.  This part covers the vast majority of the time of the entire process, under 




Figure 5.6: Impact of different variables on the release profile under flow conditions. (a) Var-
ying the inlet velocity results in a different maximum release. (b) Significant differences in the 
release profile shown during the initial release based on inlet velocity. (c) Additional uptake rate 
results in lower available resveratrol levels in the reactor. (d) Changing the length of the reactor 
does not have a significant effect on the release simulation results.   
 
5.3.5.4 Modeling the release in the presence of a porous medium.  The simulation setup was 
modified to mimic the actual microenvironment of the bone marrow or tissue surrounding the blood 
vessel.  The laminar flow was coupled with the transport of diluted chemical species in porous 
media, as well as transport of diluted chemical species.  The laminar flow was modified in the 
model to account for porous domains where the solver uses the Brinkman equation for porous do-
mains and the Navier-Stokes equation for free flow domains.  The flow was coupled with both 
transport phenomena by adding multiphysics.  The geometry was modified based on a previous 
study [137], and a porosity of 8.6% was selected using literature data [143].  For comparison pur-
poses that porosity was then doubled (17.2%) to study the effect of varying porosity on the release 
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profile.  Figure 5.7a and Figure 5.7b show the general concentration distribution at the 1000 sec-
onds, and 120 hours points in time, respectively.  The higher concentration distribution is observed 
in Figure 5.7a, in the inner cylinder, due to the higher effect of convection, and no flow resistance 
(no porosity in the inner layer).  With the progression of time, the concentration shifts towards the 
outer shell, as laminar flow washes released resveratrol in the inner cylinder due to lower flow 
resistance.  The porosity provides (Figure 5.7b) resistance for concentration drop, and hence the 
higher concentration distribution relative to the inner cylinder.  The obtained concentration profile 
shows a noticeable effect of the porous medium (Figure 5.7c).  The average, volume-based con-
centration profile in the presence of porous media is noticeably lower than that with no porous 
media, with nearly 6% reduction in the maximum level reached in the inner cylinder.  When the 
porosity is doubled, the release profile shifts further down expectedly, due to reduced resistance by 
the outer shell porous media additional diffusion path.  Thus based on where the material is im-
planted, one has to account for the diffusion through the porous medium and adjust the loading of 




Figure 5.7: Release profile and geometry of the bioreactor in the presence of flow and outer 
shell porous media. Geometric representation of the concentration distribution along the length of 
the reactor after (a) 1000 seconds of a transfer, and (b) 120 hours of transfer. (c) Release profile 
simulation of the inner reaction tube in the presence of outer shell porous media. 
 
5.4. DISCUSSION 
In this chapter, I evaluated the effect of fluid flow and cellular uptake rate on the release kinetics 
of stimulants sequestered inside electrospun fibers.  To understand the impact of fluid flow, in the 
bone marrow microenvironment, on the release of resveratrol from electrospun microfibers, a math-
ematical model was developed.  I combined the time-dependent release rate from fibers along with 
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the uptake rates by different cells.  I validated the concentration profiles from both static and dy-
namic conditions.  The model was extended by introducing an outer porous layer to further mimic 
the release in a bone marrow microenvironment.  This design includes experimental based relations, 
to define boundary conditions, and geometry.  The numerical solution of the model provides crucial 
information regarding the controlled delivery and the effect of various parameters on that process.  
The inlet velocity is typically constant on individuals basis, however, the blood perfusion rate 
slightly differs based on the individual’s age and gender [144].  This model shows the release 
mechanism does not significantly change based on inlet velocity changes within a similar scale.  
This confirms that the release process will not be affected based on the patient’s age, or gender.   
The presence of various cell types present in the blood and the blood vessel has a more significant 
effect on the release profile.  As the model predicted, however, leukemic cellular uptake is higher 
than that by healthy cells, which is the main purpose of the treatment.  The model predicted a further 
reduction in the available drug concentration as more cellular uptake is introduced.  The model 
could be enhanced by adding additional cellular and enzymatic activity, within the bone marrow 
microenvironment.  A previous model can be used as a reference for these kinetics [137].  Steady-
state transport of oxygen to the surrounding tissue is well described by the Krogh cylinder approach 
[145] and many modifications [146].  However, coupling the time-dependent release of a therapeu-
tic agent along with cellular uptake rate is not well understood.  Some have explored the release of 
various drugs sequestered into stents to mitigate restenosis issues locally [147].  Another study 
illustrated similar kinetic behavior and results for arterial drug release from stents in vivo [148].  
This shows that the model presented in this study provides an excellent base for future research.  In 
any case, compared to the proposed electrospun microfibers system in this study, stents show higher 
rigidity and better control upon the shape uniformity.   
When based on the mechanism of action, resveratrol is known to be internalized by cells.  Although 
it is not clearly understood how to control the positioning of the proposed system, it is expected 
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that perfusion rate of blood in the target bone marrow tissue will not have a significant effect on 
microfibers displacement.  It is sought to use this model as a useful tool for local delivery of resvera-
trol-encapsulated electrospun microfibers.  The microfibers can be inserted locally in the core, fatty 
inner part, of the bone marrow, after the removal of the required part.  Similar to how a biopsy is 
performed, the removed portion can be replaced with the microfibers.  This can be used as a treat-
ment [73], or to enhance treatment after chemotherapy, and a transplant, where less than 100% of 
the leukemia cells are removed [149].  The model predicts that changing the size of the bioreactor 
on a similar scale does not have a significant effect on the resultant release profile.  Hence, taking 
the suggested geometry is recommended, while other geometries can easily be tested using the 
model. 
Electrospun fibers are increasingly used in developing 3D structures.  In addition, electrospun fi-
bers are used in tissue regeneration and wound healing purposes, one could add various stimulants 
and determine the release rates [150].  With the advances in multiaxial electrospun fibers and var-
ious stimulants, one could assess the spatial distribution of components using CFD [98].  Further 
coupling of the pressure drop predictions across the scaffold, that I demonstrated previously, along 
with the nutrient consumption characteristics, one could monitor the tissue regenerative process 
[151].  However, such efforts need experimental validation.  This can be useful in other application 
based on the selected system-specific parameters.  Models, such as the one presented in this study, 
can be used to reduce animal suffering by reducing the need for in vivo testing.  The need for the 
latter might not be eliminated, however, can significantly be reduced by narrowing down experi-
mentation based on model predictions.  Similar approaches can be used to understand the release 










In aim 1, the influence of controlled release of resveratrol from electrospun microfibers, in combi-
nation with siRNA on cell viability was evaluated.  I evaluated the apoptotic and necrotic effects 
of this treatment on K562 cells using Annexin V and Propidium Iodide staining.  The combination 
effect was additive.  Non-viability analysis showed resveratrol to cause higher necrotic effects com-
pared to that of siRNA; the effect of siRNA was mainly apoptotic when introduced to the cell 
culture medium.  Fate of resveratrol in cell culture showed reduction to zero in three days.  Factorial 
design-based analysis suggested a range of effective concentrations of both drugs in achieving 
100% cell death.  In order to improve bioavailability of resveratrol, electrospun microfibers were 
successfully formed using PCL-GT combination in three different configurations.  Controlled re-
lease of resveratrol was observed for five days and its effect on cell death was confirmed, inducing 
higher apoptotic effect, using three different configurations.  Upon the controlled release of 40 µM 
resveratrol from single fibers, roughly 45% non-viable leukemia cells, after 8 days of incubation 
was measured.  However, this percentage dropped to roughly 20% in the presence of 36 nM free 
BCR-ABL siRNA, which lead to further analysis in aim 2. 
In aim 2, the effect of siRNA-loaded liposomes, in combination with controlled release of resvera-
trol on cell viability, was assessed.  
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The second delivery system is introduced to provide better control on the diffusion-dependent re-
lease, and eliminate possible side interactions.  Liposomes 123 (±6.65) nm in size were formed 
using established techniques.  Extrusion and dialysis were performed to obtain the desired size and 
purity.  Holo-transferrin was conjugated to the surface of liposomes by a thiolation reaction, with 
85.9 (±7.30)% conjugation efficiency.  Roughly 50% of non-viable leukemia cells was measured 
after treatment.  PCL-GT microfibers containing resveratrol were then introduced in combination 
with siRNA-containing holo-transferrin-derived nano-liposomes.  The treatment was tested in both 
single cultures of K562 cells, and co-cultures, in the presence of HUVECs.  The treatment intro-
duction was tested in a timely manner, showing that the delayed addition of liposomes increases 
K562 non-viability to 92.7 (±2.00)% and 94.32 (±1.70)%, in the absence and presence of HUVECs, 
respectively.  HUVECs non-viability level was significantly lower.  To better understand the im-
pact of fluid flow, present in a biological microevironment, a CFD model was built and various 
parameters were tested as part of aim 3. 
In aim 3, experiments were performed to study the stability of resveratrol in different medium and 
cellular presence conditions.  The release profile was analyzed experimentally and was also simu-
lated under both flow and non-flow conditions.  These results validated as the experimental data 
supported that predicted by the model in each case.  Several variables were then tested using the 
model, such as inlet velocity, cellular uptake rate, bioreactor’s length, and outer shell porous media.  
Results show that the release profile is mainly impacted by cellular uptake and the presence of 
porous media.  The model provides a powerful tool that predicts the behavior of the release profile 
generated by the proposed delivery method.  This delivery method can be implemented as a local 




Numerous single and multi-drug treatments have been explored, both in vitro and in vivo, for their 
potential in treating cancer.  Although the studies have shown the main effects of these treatments 
on cancer cells, further information is required.  This includes treatment’s effect on cellular path-
ways, and cellular processes, such as apoptosis and autophagy.  To minimize side effects, lower 
the required dosage, and enhance drug release control, drug delivery devices are designed and mod-
ified mainly for targeting purposes.  In this project, a novel drug delivery system has been intro-
duced with a promising potential in treating leukemia.  It is sought that this project can be used as 
a background for future studies in this area.   
The author foresees a great advantage in combining two different delivery vehicles for the purposes 
of delivering multiple, different drugs.  This method enables better control upon the release of both 
locally and systemically administered drugs.  It further provides a way to control the time of ad-
ministration of each drug, and whether simultaneous, or scheduled effect of each drug, is required.  
For example, microfibers can be locally administered, and the drug release can be modeled and 
controlled, as opposed to systemic administration of nanoparticles, which is eventually determined 
by cellular uptake alone.  In addition to the controlled release, electrospun microfibers allow a 
higher loading capacity relative to that of nanoparticles.  For instance, some drugs are effective 
when administered in the micromolar range, while no effect is observed with lower doses.  In such 
cases, nanoparticles provide maximum loading capacity that is not sufficient, or that would require 
high nanoparticles concentration.  One study shows that the maximum loading capacity of 75 mil-
lion-mole of doxorubicin per mole of liposomes [152].  Accordingly, I suggest that a researcher 
should follow a selection process to determine the appropriate combination delivery for their treat-
ment under study.  
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This method, like others, is associated with certain drawbacks.  To address some, local administra-
tion might be challenging.  It might introduce further unforeseen problems when tested in vivo, or 
in clinical trials.  Such delivery vehicles are to be scaled up if successful.  This introduces more 
challenges regarding time and cost of manufacturing.  The overall take away message is to take the 
state of the art introduced in this work, as a starting point for future studies in the delivery of com-
bination therapies for cancer treatment. 
Results of simulation show that the release profile is mainly impacted by cellular uptake and the 
presence of porous media, provided a realistic geometry and flow conditions as that found in a bone 
marrow microenvironment.  This model provides a powerful tool that predicts the behavior of the 
release profile generated by the proposed delivery method.  This delivery method can be imple-
mented as a local treatment, and based on the model, is mainly controlled by mass transfer.  It is 
recommended to further extend this study to investigate the diffusion of drug molecules inside the 
fibers.  This can be done by varying the ratio of PCL to GT in the core fiber gel.  To further enhance 
the diffusion model, the diffusion coefficient discussed earlier, can be included.  The overall diffu-
sion process can then be broken down into three major steps: (1) diffusion of resveratrol within the 
fiber core, (2) transfer of resveratrol molecules through the interface between fiber surface and cell 
medium, and (3) diffusion through cell medium.  The partition coefficient provides information 
about the concentration ratio at the interface between the two mediums at equilibrium. 
I have also successfully shown that applying chemical engineering tools in the field of pharmaceu-
ticals is a powerful addition to the field.  Models, such as the one presented in this study, can be 
used to reduce animal suffering by reducing the need for in vivo testing.  The need for the latter 
might not be eliminated, however, can significantly be reduced by narrowing down experimenta-
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SPECIFIC AIM 1         
Evaluate the influence of con-
trolled release of resveratrol, in 
combination with siRNA on cell 
viability 
    
    
SPECIFIC AIM 2         
Assess the effect of siRNA-loaded 
liposomes, in combination with 
controlled release of resveratrol 
on cell viability 
    
    
SPECIFIC AIM 3         
Design a bioreactor to mimic the 
bone marrow microenvironment, 
and study the latter’s effect on the 
proposed treatment 
    
    
Repeat Failed Experiments         
Data Analysis         








SUPPLEMENTARY STATISTICAL, FLOW CYTOMETRY, AND QPCR DATA 
B.1 ANOVA Analysis 
Anova: Single Factor method was used in excel to perform all statistical analysis shown in the 






B.2 Histogram plots- non-viability determination procedure 
A cell quest software was used to obtain histogram and dot plot for samples analyzed in non-
viability experiments.  The histogram plots were statistically analyzed to obtain the percentage of 
non-viable (in case of Annixen V staining) and necrotic (in case of PI staining).  A default log-log 
scale is set for each stain.  
After running samples in the flow cytometer, readings were recorded on the template file in Cell 




The purple curve refers to a control population incubated for 3 days. Based on that control, non-
viability analysis is determined for the green (siRNA-loaded PEG-liposomes) and pink (siRNA-
loaded Holo-Transferrin-Conjugated PEG-liposomes) after 3 days of incubation.  
Statistical analysis is obtained in Cell Quest as follows: 
Control sample: 
 
siRNA-loaded PEG-liposomes sample: 
 







Dot plots were also generated and the difference between live and dead populations is clearly 
observed. Side scatter is plotted against forward scatter, where the top controls, and the bottom is 
siRNA-loaded Holo-Transferrin-Conjugated PEG-liposomes sample: 
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